



US005474920A

# United States Patent [19]

## Moses

[11] Patent Number: 5,474,920  
[45] Date of Patent: Dec. 12, 1995

[54] MODIFIED THERMO-RESISTANT DNA POLYMERASES

[75] Inventor: Robb E. Moses, Portland, Oreg.

[73] Assignee: State of Oregon, Acting by and Through the Oregon State Board of Higher Education on Behalf of the Oregon Health Sciences University, Portland, Oreg.

[21] Appl. No.: 156,020

[22] Filed: Nov. 23, 1993

[51] Int. Cl. 6 C12N 9/12

[52] U.S. Cl. 435/194; 435/252.3; 536/23.2; 935/10; 935/14

[58] Field of Search 435/194, 252.3; 536/23.2; 935/10, 14

[56] References Cited

U.S. PATENT DOCUMENTS

- 4,399,216 8/1983 Axel ..... 435/6  
4,419,446 12/1983 Howley et al. ..... 435/68  
4,601,798 7/1986 Jacobert et al. ..... 204/61  
4,683,202 7/1987 Mullis ..... 435/91  
4,711,845 12/1987 Gelfand et al. ..... 435/68  
4,889,818 12/1989 Gelfand et al. ..... 435/194

FOREIGN PATENT DOCUMENTS

- WO92/06200 4/1992 .  
198864 8/1986 European Pat. Off. .

OTHER PUBLICATIONS

- Itakura et al., *Science*, vol. 198, 9 Dec. 1977, pp. 1056-1063.  
Joyce et al., *J. Mol. Biol.*, (1985), 186:283-293.  
Mullis et al., *Cold Spring Harbor Symp. Quant. Biol.* 51, 263 (1986).  
Mullis and Faloona, *Methods Enzymol.* 155, 335 (1987).  
Saiki et al., *Science* 239, 487 (1989).  
Lawyer et al. *J. Biol. Chem.* 264, 6472-6437 (1989).  
Longley et al., *Nuc. Acids Res.* 18, 7317-7322 (1990).  
Blanco et al., *Gene* 100, 27-38 (1991).  
Bernad et al., *Cell* 59, 219-228 (1989).  
Holland et al., *Proc. Natl. Acad. Sci.* 88, 7276-7280 (1991).  
Kelly and Joyce, *J. Mol. Biol.* 164, 529-560 (1983).  
Barnes et al., *Gene* 112, 29-35 (1992).  
Tindall and Kunkel, *Biochemistry* 27, 6008-6012 (1988).

Bolivar et al., *Gene* 2, 95-113 (1977).  
Goeddel et al., *Nucleic Acids Res.* 8, 4057 (1980).

Shimatake et al., *Nature* 292, 129 (1981).  
Broach, *Meth. Enz.* 101, 307 (1983).  
Stinchcomb et al., *Nature* 282, 39 (1979).  
Tschumper et al., *Gene* 10, 157-166 (1980).  
Clarke et al., *Meth. Enz.* 101, 300 (1983).  
Hess et al., *J. Adv. Enzyme Reg.* 7, 149 (1968).  
Hitzeman et al., *J. Biol. Chem.* 255, 12073-12080 (1980).  
Broach, *Gene* 8, 121-133 (1979).  
Fiers et al., *Nature* 273, 113-120 (1978).

Depicker et al., *J. Mol. Appl. Gen.* 1, 561-573 (1982).  
Miller et al., *Genetic Engineering* 8, 277-297 (Setlow et al., eds., Plenum Publishing 1986).

Cohen et al., *Proc. Natl. Acad. Sci. (USA)* 69, 2110-2114 (1972).

Holland et al., *J. Biol. Chem.* 256, 1385-1395 (1981).

Shaw et al., *Gene* 23, 315-330 (1983).

Graham and van der Eb, *Virology* 52, 456-467 (1973).

Van solingen et al., *J. Bact.* 130, 946-947 (1977).

Hsiao et al., *Proc. Natl. Acad. Sci. (USA)* 76, 3829-3833 (1979).

Maxam and Gilbert, *Methods in Enzymology* 65, 499-560 (1980).

Sanger et al., *Proc. Natl. Acad. Sci. (USA)* 74, 5463-5467 (1977).

Sanger, *Science* 214, 1205-1210 (1981).

Innis et al., *Proc. Natl. Acad. Sci.* 85, 9436-9440 (1988).

Tabor et al., *J. Biol. Chem.* 262, 16212-16223 (1987).

Wernette et al., *Biochem.* 27, 6046-6054 (1988).

Primary Examiner—Robert A. Wax

Assistant Examiner—Keith D. Hendricks

Attorney, Agent, or Firm—Banner & Allegretti, Ltd.


[57]

## ABSTRACT

Novel, modified Taq DNA polymerases and genes encoding for them are disclosed. The modified Taq DNA polymerases of the invention are the same size, have the same heat stability and synthesis rate as the native enzyme, but lack the 5'-3' exonuclease activity. As a result of this modification, the enzymes have improved processivity as compared to the native enzyme.


The enzymes of the present invention enable improved methods of conducting PCR, DNA sequencing, and DNA synthesis.

12 Claims, 8 Drawing Sheets



Restriction map of gene for Taq DNA polymerase

**FIG. 1**

**Scheme for Zone Mutagenesis****FIG. 2**

## Sequencing Primers for pLSM5





FIG. 3



**FIG. 4**




FIG. 5

AmpliTaq      Stoffel      REM-T2      REM-T3A





FIG. 6

## PCR Analysis of Processivity



template for PCR and  
primer position

denaturation and annealing

synthesis under conditions of  
limiting enzyme to decrease  
probability of re-initiation of  
partially extended primer

length of extended primer  
will equal processivity

multiple PCR cycles

if the length of extended primer  
includes the gap and primer, the PCR  
product will be formed

**FIG. 7**

**1 2 3 4 5 6 7 8**

**117 →**



**FIG. 8**

## MODIFIED THERMO-RESISTANT DNA POLYMERASES

This invention was made with the Government support under grant GM 24711 awarded by the National Institutes of Health. The Government has certain rights in the invention.

### BACKGROUND OF THE INVENTION

#### 1. Field of the Invention

This invention relates to the field molecular biology, specifically with reference to the subject of DNA polymerases for use in the polymerase chain reaction and DNA sequencing.

#### 2. Description of the Prior Art

Polymerase Chain Reaction (PCR) was one of the most important inventions developed in area of biotechnology during the 1980's and has proven useful for a variety of tasks. *PCR Technology, Principles and Applications for DNA Amplification* (Erlich ed. 1989). The process provides a method for amplifying known specific nucleic acid sequences. Mullis, U.S. Pat. No. 4,683,202. The process comprises treating single- or double-stranded DNA containing the sequence of interest with an excess of two oligonucleotide primers sufficiently complementary of the strands so as to hybridize to the denatured strands. The hybridized primers are then extended by a DNA polymerase in the presence of the four dNTPs. The primer extension products are then separated and can serve as templates for another cycle of replication. The number of DNA templates approximately doubles on each cycle of amplification. Thus, 20 cycles of the process will result in approximately a  $2^{20}$ -fold amplification.

The original protocols for PCR used the Klenow fragment of *E. coli* DNA polymerase I to catalyze the extension of the oligonucleotide primers. Mullis et al., *Cold Spring Harbor Symp. Quant. Biol.* 51, 263 (1986); Mullis and Faloona, *Methods Enzymol.* 155, 335 (1987). The Klenow fragment proved somewhat cumbersome to use. Denaturation of the double stranded DNA at the start of each cycle requires temperatures ranging from 80° to 105° C. These temperatures inactivate the Klenow fragment. Consequently, fresh enzyme was required at the start of each new amplification cycle. While this process generally worked well for small segments of DNA (<200 bp), a host of problems arose when replication of larger fragments was attempted.

The difficulties associated with use of the Klenow fragment DNA polymerase were circumvented with the introduction of thermostable DNA polymerase obtained from the thermophilic bacterium *Therrnus aquaticus* (Taq DNA polymerase). Saiki et al., *Science* 239, 487 (1989); Gelfand et al., U.S. Pat. No. 4,889,818. This enzyme has been cloned, overproduced, and the DNA sequence determined. Lawyer et al., *J. Biol. Chem.* 264, 6427-6437 (1989).

In addition to its DNA polymerase activity, Taq DNA polymerase also possesses 5'-3' polymerization-dependent exonuclease activity, but it lacks 3'-5' exonuclease activity. Longley et al., *Nuc. Acids Res.* 18, 7317-7322 (1990); Blanco et al., *Gene* 100, 27-38 (1991); Bernad et al., *Cell* 59, 219-228 (1989); Lawyer et al., supra; Holland et al., *Proc. Natl Acad. Sci.* 88, 7276-7280 (1991); and Kelly and Joyce, *J. Mol. Biol.* 164, 529-560 (1983). Studies have identified the 5'-3' exonuclease activity as being an intrinsic part of Taq DNA polymerase. Longley et al., supra; and Barnes et al., *Gene* 112, 29-35 (1992). This activity appears to facilitate a nick translation DNA reaction.

Native Taq DNA polymerase suffers from a high rate of misincorporation— about four times higher than that of the Klenow fragment of *E. coli* DNA polymerase I. It has been estimated that Taq DNA polymerase incorporates one incorrect nucleotide in 9000. Tindall and Kunkel, *Biochemistry* 27, 6008 (1988). After 20 amplification cycles, this would result in DNA molecules with random mutations averaging one in every 900 bases. Saiki et al., supra. If the PCR product is to be inserted into an expression vector, the chance that one cloned molecule will contain an unwanted sequence alteration may be significant. It would be desirable, therefore, to decrease the rate of misincorporation of the DNA polymerase used in PCR without sacrificing the heat stability and rate of synthesis of the native Taq DNA polymerase.

It has been shown that removal of the 5'-most 235 codons of the Taq DNA polymerase gene results in an expression product that has no 5'-3' exonuclease activity and a lower rate of mutagenesis. Tindall et al., supra; and Barnes, supra.

Other forms of Taq DNA polymerase are available. AmpliTaq™ is a commercially available genetically engineered version of Taq DNA polymerase and is substantially equivalent to the native form. Perkin Elmer Cetus; Saiki and Gelfand, *Amplifications* (Perkin Elmer Cetus), 1, 4 (1989). Also commercially available is a truncated gene product, the Stoffel fragment, that expresses an enzyme lacking the 5'-3' exonuclease activity and having much lower unit activity, probably due to decreased processivity and increased mutagenesis. Barnes, supra. Gelfand and Abramson (PCT International Publication No. WO 92/06200) disclosed a modified Taq polymerase having the same length as the native enzyme, but with highly attenuated 5'-3' exonuclease activity. The exonuclease activity is defeated by mutation in nucleotide 137 of the Taq polymerase gene, wherein the mutation is G to A, resulting in a change in amino acid 46 of the enzyme from Gly to Asp. This enzyme is reported as having the same polymerase activity, processivity and extension rate as the native enzyme.

### SUMMARY OF THE INVENTION

An object of this invention is to enhance the synthesis activity of DNA polymerase as used in PCR and DNA sequencing.

The invention disclosed herein achieves this object by providing a modified Taq DNA polymerase and a correspondingly modified Taq DNA polymerase gene sequence. The modified Taq DNA polymerase is the same size, has the same heat stability and synthesis rate as the native enzyme, but the 5'-3' exonuclease activity is missing. As a result of this modification, the gene expression product has improved processivity.

The enzymes of the present invention enable improved methods of conducting PCR, DNA sequencing and DNA synthesis.

### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graphical depiction of the restriction map of the Taq DNA polymerase gene.

FIG. 2 is a graphical depiction of the method for producing the modified Taq DNA polymerase and the gene encoding it.

FIG. 3 shows the sequencing primers for the pLSM5 (SEQ ID NO: 3) plasmid.

FIG. 4 is a schematic depiction of the method for testing processivity used in trials 1 and 2.

FIG. 5 is the autoradiograph showing the results of processivity testing used in trial 1.

FIG. 6 is the autoradiograph showing the results of processivity testing used in trial 2.

FIG. 7 is a schematic depiction of the method for testing processivity using PCR.

FIG. 8 is the autoradiograph showing the results of processivity testing by the PCR method.

#### DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term "replication product" refers to the oligonucleotides synthesized by DNA polymerase, whether it be as part of the polymerase chain reaction, DNA sequencing, or any other reaction where DNA polymerase is used to synthesize an oligonucleotide.

The term "oligonucleotide" as used herein is defined as a molecule composed of two or more deoxyribonucleotides or ribonucleotides.

The term "thermostable" refers to an enzyme that is stable to heat (>95° C.) and catalyzes combination of nucleotides to form an oligonucleotide. The term "thermo stability" as used herein refers to the characteristic stability of an enzyme to heat.

As used herein, the term "altered amino acid" means an amino acid that differs from that found in the native peptide or protein. Hence, if the native peptide has the amino acid Cys at position 43, and the modified peptide has the amino acid Gly at that position, Gly is the "altered amino acid." Similarly, the term "altered nucleotide" means a nucleotide that differs from that found in a native oligonucleotide, polynucleotide, gene, or other nucleotide fragment.

As used herein, the phrase "lacking 5'-3' exonuclease activity" means an enzyme having less than 1% of the 5'-3' exonuclease activity of the native Taq DNA polymerase.

We undertook to inactivate the 5'-3' exonuclease activity of the Taq DNA polymerase by *in vitro* mutagenesis without removal of the portion of the gene encoding that activity. The procedure followed was to develop a method of "zone mutagenesis" for that region of the Taq DNA polymerase gene encoding for the 5'-3' exonuclease activity. See FIG. 2. Although the particular nucleotides encoding the amino acid residues required for 5'-3' exonuclease activity have not been clearly identified, earlier work suggested a region analogous to the region involved in DNA polymerases from other bacteria. Kelly and Joyce, *supra*.

To briefly summarize, using PCR technology we generated a Taq gene, which we cloned into the plasmid vector pUC18. See FIG. 1. The pUC18 plasmid containing the Taq gene is designated pLSM5 (SEQ ID NO: 3). Four base changes in the Taq gene were produced by PCR and cloned in pLSM5 (SEQ ID NO: 3) compared to the published Taq DNA polymerase gene sequence (available under the accession code "TTHTAQPIA" in GenBank) (SEQ ID NO: 1): 1) C to G at position 89 in the untranslated 5' end, 2) T to A at position 934 (Phe to Ile), 3) T to C at position 962 (Leu to Pro), and 4) G to A (resulting in no amino acid change) at position 2535. The protein expression product of this gene has an altered amino acid at positions 272 (Ile) and 281 (Pro). We then subjected the pLSM5 (SEQ ID NO: 3) plasmid to conditions that would cause the random mutations in the 5' exonuclease domain.

The vector encoding the Taq gene (pLSM5 (SEQ ID NO: 3) producing the enzyme REM-T2 (SEQ ID NO: 4)) begins

at nucleotide 70 and ends at 2619. The reading frame for translation begins at nucleotide 121 and ends at 2619 by the convention of Lawyer et al., *J. Biol. Chem.* 264, 6427-6437 (1989).

5 The following sequence appears at the 5' junction between the pUC18 plasmid and the Taq gene:

AATTCACACAGGAAACAGCTATGAC-CATGATTACGAATTCTAAA . . . (SEQ ID NO: 14)

This sequence begins with the pUC18 antisense nucleotide sequence 490 to 455. The underlined nucleotides (AA) were added to create a restriction site. The Taq gene sequence (bold face) begins at nucleotide 70.

The following sequence appears at the 3' junction between the pUC18 plasmid and the Taq gene:

CAAGGAGTGA-GATTCTCTAGAGTCGACCTGCAGGCATGCAAGC-TTGGCACT GGCGTCGTTT . . . (SEQ ID NO: 15)

This sequence begins with Taq polymerase gene nucleotide 2610 to 2619. The underlined nucleotides (GA) were added to create a restriction site. The remaining sequence is the pUC18 antisense nucleotide, 413 to 381. Both junction sequences have been verified by sequence analysis.

15 The enzyme expression product of the pLSM5 plasmid, REM-T2 (SEQ ID NO: 4), has substantially the same processivity, 5'-3' exonuclease activity, and performance in normal PCR, to the extent tested so far, as the commercially available Taq DNA polymerase AmpliTaq™.

A variety of methods of mutagenesis are known to those of skill in the art and may be used in preparing a modified 20 Taq DNA polymerase gene according to the present invention. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, 2d Ed. 1989). These include, for example, site-directed 25 mutagenesis using single-stranded cloned isolates of the

30 nucleotide sequence to be mutated by annealing and extension of a homologous primer containing the desired mutation, followed by re-introduction and selection in bacteria. Also within the skill of one of ordinary skill in this art is the use of numerous PCR-based protocols, for introducing 35 mutations either in a site-specific or random fashion. In the instant invention, genes mutated using such techniques were thereafter treated with restriction endonucleases that cut in the region believed to be responsible for 5'-3' exonuclease 40 activity, thereby producing mutated inserts coding for that portion of the gene. A vector containing the native Taq DNA 45 polymerase gene was treated with the same endonucleases and the previously-isolated mutant inserts ligated into the vector. Cells were transformed with the vector containing the 50 inserts and colonies grown. We assayed polymerases expressed by the various colonies for polymerase activity as 55 well as 5'-3' exonuclease activity. The cells transfected with the gene encoding the modified Taq DNA polymerase meeting the objective of the present invention were thereby identified.

Appropriate host cells for the present invention may be chosen from the prokaryote group, which most frequently 60 are represented by various strains of *E. coli*. Other microbial strains such as bacilli may be used, however. *Bacillus subtilis* and various species of *Pseudomonas* may be used, for example. In such prokaryotic systems, plasmid vectors 65 that contain replication sites and control sequences derived from a species compatible with the host are used. For example, *E. coli* is typically transformed using derivatives of pBR322, a plasmid derived from an *E. coli* species by Bolivar, et al., *Gene* 2, 95 (1977). pBR322 contains genes for ampicillin and tetracycline resistance, and thus provides addition markers that can be either retained or destroyed in

constructing the desired vector. Commordy used prokaryotic control sequences, which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequence, include such commonly used promoters as the *g*-lactamase (penicillinase) and lactose (*lac*) promoter systems (Chang, et al., *Nature* 198, 1056 (1977)), the tryptophan (*trp*) promoter system (Goeddel, et al., *Nucleic Acids Res.* 8, 4057 (1980)), the lambda-derived PL promoter (Shimatake et al., *Nature* 292, 129 (1981)), and the N-gene ribosome binding site, which has been made useful as a portable control cassette (U.S. Pat. No. 4,711,845). The N-gene ribosome binding site comprises a first DNA sequence that is the PL promoter operably linked to a second DNA sequence corresponding to NRBS upstream of a third DNA sequence having at least one restriction site that permits cleavage within six bp 3' of the NRBS sequence. Also useful is the phosphatase A (*phoA*) system described by Chang et al. in European Patent Publication No. 196,864 published Oct. 8, 1986. Any available promoter system compatible with prokaryotes can be used, however.

In addition to bacteria, eucaryotic microbes, such as yeast, may also be used as hosts. Laboratory strains of *Saccharomyces cerevisiae*, Baker's yeast, are most used, although a number of other strains are commonly available. While vectors employing the 2 micron origin of replication are illustrated (Brach, *Meth. Enz.* 101, 307 (1983)), other plasmid vectors suitable for yeast expression are known (see, e.g., Stinchcomb et al., *Nature* 282, 39 (1979), Tschempe et al., *Gene* 10, 157 (1980), and Clarke et al., *Meth. Enz.* 101, 300 (1983)). Control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes. Hess et al., *J. Adv. Enzyme Reg.* 7, 149 (1968) and Holland et al., *Biotechnology* 17, 4900 (1978).

Additional promoters known in the art include the promoter for 3-phosphoglycerate kinase (Hitzeman et al., *J. Biol. Chem.* 255, 2073 (1980) and those for other glycolytic enzymes, such as glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other promoters that have the additional advantage of transcription controlled by growth conditions are the promoter regions for alcohol dehydrogenase 2, isocytchrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and enzymes responsible for maltose and galactose utilization. Holland, supra.

It is also believed that terminator sequences are desirable at the 3' end of the coding sequences. Such terminators are found in the 3' untranslated region following the coding sequences in yeast-derived genes. Many of the vectors illustrated contain control sequences derived from the enolase gene containing plasmid peno46 (Holland et al., *J. Biol. Chem.* 256, 1385 (1981) or the LEU2 gene obtained from YEp13 (Broach et al., *Gene* 8, 121 (1978). Any vector containing a yeast-compatible promoter, origin of replication, and other control sequence is suitable, however.

It is also possible to express genes encoding polypeptides in eucaryotic host cell cultures derived from multicellular organisms. See, e.g., *Tissue Culture* (Cruz and Patterson eds., Academic Press 1973). Useful host cell lines include murine myelomas N51, VERO and HeLa cells, and Chinese Hamster Ovary (CHO) cells. Expression vectors for such cells ordinarily include promoters and control sequences compatible with mammalian cells such as the commonly used early and late promoters from Simian Virus 40 (SV 40)

(Fiefs et al., *Nature* 273, 113 (1978)) or other viral promoters such as those derived from polyoma, Adenovirus 2, bovine papilloma virus, or avian sarcoma viruses, or immunoglobulin promoters and heat shock promoters. A system for expressing DNA in mammalian systems using the BPV as a vector is disclosed in U.S. Pat. No. 4,419,446. A modification of this system is described in U.S. Pat. No. 4,601,978. General aspects of mammalian cell host system transformations have been described by Axel, U.S. Pat. No. 4,399,216. It now appears that "enhancer" regions are important in optimizing expression. These generally are sequences found upstream of the promoter region. Origins of replication may be obtained from viral sources. Integration into the chromosome, however, is a common mechanism for DNA replication in eucaryotes.

Plant cells are also now available as hosts. Control sequences compatible with plant cells such as the nopaline synthase promoter and polyadenylation signal sequence are available. Depicker et al., *J. Mol. Appl. Gen.* 1, 561 (1982).

In addition, expression systems employing insect cells utilizing the control systems provided by baculovirus vectors have been described. Miller et al., *Genetic Engineering* 8, 277-297 (Setlow et al. eds. Plenum Publishing 1986). These systems are also successful in producing Taq DNA polymerase.

Cells transformed with the modified Taq DNA polymerase gene may be grown using any suitable technique. The appropriate technique will depend on the cell type and will be known to those skilled in the art.

Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The treatment employing calcium chloride is used for prokaryotes or other cells that contain substantial cell wall barriers. Cohen, *Proc. Natl. Acad. Sci. (USA)* 69, 2110 (1972). Infection with *Agrobacterium tumefaciens* is used for certain plant cells. Shaw et al. *Gene* 23, 315 (1983). For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb is preferred. *Virology* 52, 546 (1978). Transformations into yeast are carried out according to the method of Van solingen et al., *J. Bact.* 130, 946 (1977) and Hsiao et al., *Proc. Natl. Acad. Sci. (USA)* 76, 3829 (1979).

Construction of suitable vectors containing the desired coding and control sequences employs standard ligation and restriction techniques that are well understood in the art. Isolated plasmids, DNA sequences, or synthesized oligonucleotides are cleaved, tailored, and reassembled in the form desired.

Site-specific DNA cleavage is performed by treating with the suitable restriction enzyme (or enzymes) under conditions that are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes. See, e.g., *New England Biolabs, Product Catalog*. In general, about 1 µg of plasmid or DNA sequence is cleaved by one unit of enzyme in about 20 µl of buffer solution. Often excess of restriction enzyme is used to ensure complete digestion of the DNA substrate. Incubation times of about one hour to two hours at about 37° C. are workable, although variations are tolerable. After each incubation, protein is removed by extraction with phenol/chloroform, and may be followed by ether extraction. The nucleic acid may be recovered from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. A general description of size separations is found in *Methods in Enzymology* 65, 499-560 (1980).

Cells producing Taq polymerase enzyme of the desired type can be identified by standard techniques for assaying DNA polymerase and 5'-3' exonuclease activity. Id. Using some of these methods, we were able to isolate a Taq DNA polymerase having the same size, heat stability, and synthetic activity of native Taq DNA polymerase, but having increased processivity and resulting in decreased mutagenesis of PCR DNA products. See examples infra.

The modified Taq DNA polymerase of the present invention was chosen from a colony producing the enzyme with a relatively high polymerase activity and low 5'-3' exonuclease activity. We designated this product REM-T3 (SEQ ID NO: 6). An equivalent independently isolated product with a different mutation but equivalent properties is designated REM-T5 (SEQ ID NO: 8).

In addition to the modifications of native Taq DNA polymerase present in the modified Taq DNA polymerase of the present invention, individual amino acid residues in the peptide chain comprising the Taq DNA polymerase may be modified or deleted without eliminating any of the requisite properties described herein. Such alterations that do not destroy activity do not remove the DNA sequence or the modified Taq DNA polymerase from the contemplated scope of the present invention.

In order to assay the modified Taq DNA polymerase, REM-T3 (SEQ ID NO: 6), it was necessary to isolate it. We used the following novel, short isolation technique producing high purity enzyme quickly. Bacteria were grown overnight or to an OD at 600 nm of about 2.0 to 2.5 and then centrifuged at 5000 rpm for 10 minutes. The supernatant was discarded and the pellet washed with a solution of 50 mM Tris(8.0), 50 M dextrose, and 1 mM EDTA (15×cell wt). The pellet was re suspended and lysed with a solution of 50 mM Tris, 50 mM dextrose, 1 mM EDTA, and 1 mg/ml lysozyme(5×cell wt). An equal volume of a solution of 10 mM Tris and 50 mM KCl, and 1 mM EDTA was added and the resulting mixture incubated at 75° C. for 60 min before centrifuging at 8000 rpm for 15 min. The pellet was discarded and an equal volume of DEAE and 0.4 M KPO<sub>4</sub> (6.8) was added to the supernatant. The mixture was then incubated at 0° C. for 30 min and then centrifuged at 10,000 rpm for 20 min. The pellet was discarded and the supernatant put on a phosphocellulose column with 0.02 M KPO<sub>4</sub> (7.5)(4× cell wt). The column was eluted with a gradient of 0.02 to 0.4 M KPO<sub>4</sub> (7.5). The peak was collected and applied to a Bio Rex-70 column with a solution of 0.02 M KPO<sub>4</sub> (7.6), 80 mM KCl 5%, glycerol, 0.5% Tween, and 0.5% Nonidet P-40. This column was then eluted with a step gradient of 0.3 M KCl and the peak collected.

The thermostability of the modified Taq DNA polymerase of the present invention must be substantially equivalent to that of native Taq DNA polymerase, i.e., it must not become irreversibly denatured (inactivated) when subjected to the elevated temperatures for the time necessary to effect denaturation of double-stranded nucleic acids. The heating conditions (e.g., temperature and time) necessary for denaturation will depend on a variety of factors, including the buffer salt concentration and the length and composition of the nucleotide chain. Typically, the temperature range for which the enzyme must be stable is about 90 to about 105° C. for about 0.5 to four minutes. These values may vary depending on the conditions.

The modified Taq DNA polymerase of the present invention preferably functions optimally at temperatures above 40° C. The enzymes of the present invention is active in the temperature range 55°–95° C., and preferably in the range 70°–95° C.

U.S. Pat. No. 4,889,818 discloses and claims a native form of Taq DNA polymerase. Because the modified Taq DNA polymerase of the present invention retains all the characteristics of the native form that are useful in PCR technology, its use in PCR is preferable to the native form. Consequently, applications using Taq DNA polymerase as described in U.S. Pat. No. 4,889,818, col. 14, 1.33 to col. 27, 1. 27 may also use the modified Taq DNA polymerase of the present invention. Accordingly, the disclosure of U.S. Pat. No. 4,889,818 is hereby incorporated by reference.

Besides use in the polymerase chain reaction, the modified Taq DNA polymerase of the present invention can be used in DNA sequencing by, for example, the Sanger dideoxy-mediated chain-termination method. Sanger et al., *Proc. Natl. Acad. Sci.* 74, 5463 (1977). Other similar uses will be known to those of skill in the art.

The following examples further elucidate the present invention, but are not intended to limit it.

## EXAMPLE 1

### Zone Mutagenesis of the Taq DNA Polymerase Gene—Treatment 1

The Taq polymerase gene was amplified from genomic DNA (*Thermus aquaticus*) using primers adding an EcoRI site in the 5' UTR (nucleotide 70) and BgII site at the 3' end (nucleotide 2619). The PCR product was cloned into pUC18 after digesting the vector with EcoRI and BamHI. See FIG. 1. We designated this Taq gene REM-T2. We then incubated the plasmid containing the Taq gene at pH 4.8 (10 mM sodium acetate) and room temperature for 20 minutes followed by neutralization to pH 8.0 with 50 mM Tris HCl. Inserts for the putative amine terminal region of the gene were generated by PCR using the “reverse primer” for pUC18 (CAG GAA ACA GCT ATG ACC (SEQ ID NO: 11) and the “sequencing primer” 628A (CCC AAA GCC AGG CCG (SEQ ID NO: 12)) followed by digestion with Eco RI and KpnI.

The pLSM5 (SEQ ID NO: 3) vector was digested with EcoRI and KpnI and purified. The inserts previously generated were then inserted into this vector. Ligation for insertion of the modified Taq gene was followed by transformation of DH5a cells followed by growth of individual colonies with assay for the DNA polymerase activity and the 5'-3' exonuclease activity.

## EXAMPLE 2

### Zone Mutagenesis of the Taq DNA Polymerase Gene—Treatment 2

Using PCR, we generated a Taq gene (REM-T2), which we cloned into the plasmid vector pUC18. See FIG. 1. We incubated the plasmid DNA containing the Taq gene at pH 4.8 and 60° C. for 5 minutes followed by neutralization to pH 8.0 with 50 mM Tris HCl. Inserts for the putative amine terminal region of the gene were generated by PCR using the “reverse primer” for pUC18 (CAG GAA ACA GCT ATG ACC (SEQ ID NO: 11)) and the “sequencing primer” 628A (CCC AAA GCC AGG CCG (SEQ ID NO: 12)) followed by digestion with Eco RI and KpnI.

A vector encoding the Taq gene (pLSM5 (SEQ ID NO: 3) producing the enzyme REM-T2 (SEQ ID NO: 4)) was digested with Eco RI and KpnI and purified. The inserts previously generated were then inserted into this vector. Ligation for insertion of the modified Taq gene was followed

by transformation of DH5a cells followed by growth of individual colonies with assay for the DNA polymerase activity and the 5'-3' exonuclease activity.

#### EXAMPLE 3

##### Zone Mutagenesis of the Taq DNA Polymerase Gene—Treatment 3

Using PCR, we generated a Taq gene (REM-T2), which we cloned into the plasmid vector pUC18. See FIG. 1. We amplified the N-terminal region of the Taq DNA polymerase gene for three consecutive PCR programs of 30 cycles each using the "reverse primer" for pUC18 (CAG GAA ACA GCT ATG ACC) and the "sequencing primer" 628A (CCC AAA GCC AGG CCG (SEQ ID NO: 12)). Inserts for the putative amino terminal region of the gene were generated by digestion of the PCR products with Eco RI and KpnI.

A vector encoding the Taq gene (pLSM5 (SEQ ID NO: 3) producing the enzyme REM-T2 (SEQ ID NO: 4)) was digested with Eco RI and KpnI and purified. The inserts previously generated were then inserted into this vector. Ligation for insertion of the modified Taq gene was followed by transformation of DH5a cells followed by growth of individual colonies with assay for the DNA polymerase activity and the 5'-3' exonuclease activity.

#### EXAMPLE 4

##### Zone Mutagenesis of the Taq DNA Polymerase Gene—Treatment 4

Using PCR, we generated a Taq gene (REM-T2), which we cloned into the plasmid vector pUC18. See FIG. 1. We incubated the plasmid DNA containing the Taq gene a pH 4.8 and 70° C. for 15 minutes followed by neutralization to pH 8 with 50 mM Tris HCl. Inserts for the putative amino terminal region of the gene were generated by PCR using the "reverse primer" for pUC18 (CAG GAA ACA GCT ATG ACC (SEQ ID NO: 11)) and the "sequencing primer" 1155A (CAG GTC CCT GAG GGC (SEQ ID NO: 13)) and 5× concentration of dNTPs (0.75 mM) followed by digestion with Eco RI and BstXI.

A vector encoding the Taq gene (pLSM5 (SEQ ID NO: 3) producing the enzyme REM-T2 (SEQ ID NO: 4)) was digested with Eco RI and BstXI and purified. The inserts previously generated were then inserted into this vector. Ligation for insertion of the modified Taq gene was followed by transformation of DH5a cells followed by growth of individual colonies with assay for the DNA polymerase activity and the 5'-3' exonuclease activity.

#### EXAMPLE 5

##### DNA Polymerase Activity Assay

###### Assay mixture:

reaction volume: 0.3 ml  
 25 mM Tris-HCl (pH=8.8)  
 4 mM MgCl<sub>2</sub>  
 22 µg activated ssDNA (salmon sperm)  
 0.033 mM dNTP (each)  
 2 µCi [methyl-<sup>3</sup>H] thymidine 5' triphosphate  
 enzyme

###### Assay procedure:

The mixture was incubated at 75° C. for 10 minutes. The reaction was stopped with 2 ml ice cold 10% TCA—0.1 M

sodium pyrophosphate. The tubes were then placed on ice for 10 minutes and the reaction volume filtered. The tube and filter were washed three times with 2 ml of 10% TCA—0.1 M sodium pyrophosphate. The filter was then washed with 10 ml 0.01 N HCl. Next the filters were dried at 120° C. for 15 minutes. The dried filters were counted in 1 ml of Scintiverse.

The results are displayed in Table 1, infra.

#### EXAMPLE 6

##### 5'-3' Exonuclease Activity Assay

Preparation of double stranded substrate with blunt ends and removal of 5' phosphate

A Blue-Script plasmid was cut with HincII to produce one double stranded piece with blunt ends and treated with CIP (calf intestine phosphatase) to remove the 5' phosphate.

###### End-labeling of the 5' ends using [ $\gamma$ -P]ATP

8 µl plasmid and 4 µl buffer were mixed with spermidine and 28 µl distilled H<sub>2</sub>O. The mixture was then heated to 70° C. for 5 minutes and then chilled on ice for 2 minutes. 10 µl kinase buffer with 1 µl [ $\gamma$ -<sup>32</sup>P]ATP (about 10 µCi) and 2 µl (20 units) of T4 polynucleotide kinase were added. Then the mixture was incubated for 30 minutes at 37° C. The reaction was stopped by adding 2 gl 0.5 M EDTA. The enzyme was inactivated by incubating for 10 minutes at 70° C. The radioactive ATP was removed by washing 4 times (2 ml each) in Centricon 100. The final volume was about 50 µl (38,000 cpm/µl).

###### 5'-3' exonuclease assay

###### Assay conditions:

reaction volume 50  
 25 mM Tris HCl (8.8)  
 4 mM Mg Cl<sub>2</sub>  
 0.5–1 µl labeled substrate  
 0.3 units of DNA polymerase

Samples were incubated at 50°–55° C. for 15, 30 or 60 minutes. The reaction was stopped with 0.3 ml 10% TCA. The sample was microfuged for 15 minutes at 4° C. 0.1 ml was sampled on filter paper. The filter paper was dried at 120° C. for 15 minutes. Dried filters were counted in 1 ml of Scintiverse.

The assay results are presented in Table 1, infra.

#### EXAMPLE 7

##### Sequencing Mutant Genes

Three mutants were chosen from those listed in Table 1 for low exonuclease activity. These were colony 18' (the plasmid of which we designate pTarf2 (SEQ ID NO: 9)) and colony 20' (the plasmid of which we designate pTarf3 (SEQ ID NO: 5)). A third mutant, pTarf5 (SEQ ID NO: 7), was obtained in a similar manner as in Example 4. pTarf3 (SEQ ID NO: 5) produces REM-T3 (SEQ ID NO: 6) and pTarf5 (SEQ ID NO: 7) produces REM-T5 (SEQ ID NO: 8). Bi-directional sequencing of the nucleic acid sequence of these mutants was conducted in the following manner: DNA sequence analysis was performed on alkaline-denatured double stranded plasmids. We used synthesized oligonucleotide primers (FIG. 3), [ $\alpha$ -<sup>35</sup>S]-dATP, and Sequenase® T7 DNA polymerase kit (United States Biochemical Corp.) according to the manufacturer's conditions. This method is based on the dideoxy chain termination reaction (Sanger, *Science* 214, 1205 (1981)).

## 11

The alterations found in the mutants are presented in Table 2. These alterations are of the pLSM5 (SEQ ID NO: 3) sequence, i.e., the pTarf2 (SEQ ID NO: 9), pTarf3 (SEQ ID NO: 5), and pTarf5 (SEQ ID NO: 7) sequences are the same as the pLSM5 (SEQ ID NO: 3) sequence except for the alterations listed in Table 2.

TABLE 1

		Enzyme Activity Of New Taq Clones	
treatment	colony	polymerase act units/ $\mu$ l	5'-3' exonuclease activity % of REM-T2 (SEQ ID NO: 4)
1	1	0.132	87
	2	0.503	97
	3	0.053	14
	4	0.27	88
	5	0.098	82
	6	0.41	94
	7	0.255	95
2	8	0.106	74
1	1'	1.54	104
	2'	1.60	94
	3'	1.06	105
	4'	1.49	100
	5'	1.06	104
	6'	2.20	114
	7'	0.35	107
	8'	0.68	117
	9'	0.74	94
	10'	0.87	109
2	11'	1.81	98
	12'	1.22	95
	13'	1.68	110
	14'	1.04	102
	15'	0.84	101
	16'	1.4	98
	17'	0.15	104
	18'	1.77	24
	19'	1.11	107
3	20'	1.73	0
	21'	0.018	6
	22'	0.48	0
	23'	1.8	105
	24'	0.83	94
	25'	0.78	93

1 unit of polymerase activity=10 nmoles of total nucleotides incorporated into acid insoluble form in 30 minutes at 75° C. Primed and unprimed colonies were obtained from cells transformed on different days.

TABLE 2

Alterations Relative to pLSM5 (SEQ ID NO: 3)				
plasmid	nucleotide position	amino acid position	codon change	amino acid change
pTarf2 (SEQ ID NO: 9)	337	73	TTC—CTC	Phe—Leu
pTarf3 (SEQ ID NO: 5)	193	25	CGC—TGC	Arg—Cys
	504	128	AAG—AAA	Lys—Lys
pTarf5 (SEQ ID NO: 7)	341	74	CGC—CAC	Arg—His

## EXAMPLE 8

## Improved Processivity of the Modified Taq Polymerase

Processivity of DNA synthesis by the modified Taq DNA polymerase (REM-T3) was assessed by several trials, with

## 12

comparison to commercial enzymes and REM-T2. The method using the PCR protocol is novel.

Trial 1: Gel analysis of processivity by thermal stable DNA polymerases.

M13mp18 template (0.25 pmol/10  $\mu$ l) and 5'<sup>32</sup>P-labeled 17-mer (M13/pUC-40, BioLabs) (0.50 pmol/10  $\mu$ l) (calculated  $t_m=52^{\circ}$  C.) were annealed in 40  $\mu$ l of 10 mM Tris-HCl (pH 8.0), and 5 mM MgCl<sub>2</sub>. The mixture was incubated for 3 minutes at 90° C., 20 minutes at 42° C., and 15 minutes at room temperature. The reaction mixture was adjusted to 200  $\mu$ M each of dNTP, 0.05% Tween 20 and Nonidet P-40, 10 mM Tris-HCl (pH 8.0), 50 mM KCl and 2.5 mM MgCl<sub>2</sub>, in a total volume of 80  $\mu$ l, then incubated at 55° C. for 2 minutes without enzyme. Next, 0.94 units of enzyme (AmpliTaq™ (Cetus), Stoffel Fragment(Cetus), REM-T2 or REM-T3)/10  $\mu$ l were added to start the reaction. Five  $\mu$ l aliquots were removed from the reaction mixture at 0, 15, 30, 45 seconds, and 1, 2, and 5 minutes and added to 5  $\mu$ l of stop solution (1 mg/ml each of xylene cyanol and bromphenol blue, 10 mM EDTA in formamide). For gel analysis, 5  $\mu$ l were loaded onto a 6% wedge acrylamide/urea gel.

FIG. 4 is a schematic depiction of the process and FIG. 5 is an autoradiograph showing the results of trial 1.

Trial 2: Gel analysis of processivity by thermal stable DNA polymerases.

The same method was used as in Trial 1, except 0.22 units of polymerase/10  $\mu$ l of reaction mixture were added. In addition, smaller volumes were used for annealing (25  $\mu$ l) and reaction mixture (50  $\mu$ l).

For trials 1 and 2, the assayed polymerase activity of the AmpliTaq™ was lower than usual. It appears from the gels that the number of actual units of AmpliTaq™ used in the reaction may have been higher than estimated and, therefore, may not be comparable to the other reactions.

FIG. 6 shows the results of trial 2. Note that when the amount of polymerase is limiting, REM-T2 (SEQ ID NO: 4) and REM-T3 (SEQ ID NO: 6) have processivities greater than that of the Stoffel fragment.

Trial 3: PCR analysis of processivity by thermal stable DNA polymerases

The final volume of PCR reaction was 50  $\mu$ l. The buffer contained 67 mM Tris-HCl (pH 8.8), 16 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 10 mM beta mercaptoethanol, 2 mM MgCl<sub>2</sub>, 6.7  $\mu$ M EDTA, and 150  $\mu$ M each dNTP. There was an excess of template (0.02 pmol/10  $\mu$ l) and primers (each 10 pmol/10  $\mu$ l) over enzyme (0.04 units of polymerase/10  $\mu$ l) for each PCR reaction. The template was pLSM5 (SEQ ID NO: 3), a 5.1 kb plasmid containing Taq DNA polymerase gene and used for sequencing. For the 834–951 primer set, at least 102 nucleotides must be added to the primers to form the 117 base pair product, and for the 1564–1937 primer set, at least 358 nucleotides must be added to the primer to form the 373 base pair product. The PCR program was 20 sec denaturation at 94° C., 30 sec annealing at 48° C., and 2 min extension at 72° C. for 12 cycles.

FIG. 7 is a schematic depiction of this process and FIG. 8 shows is an autoradiograph showing the results.

## Interpretation of Processivity Testing

Trials 1 and 2 are based on methodology similar to Innis et al., *Proc. Natl. Acad. Sci.* 85, 9436 (1988); Tabor et al., *J. Biol. Chem.* 262, 16212 (1987); and Wernette et al., *Biochem.* 27, 6046 (1988). The use of a fixed primer for synthesis under conditions of limiting enzyme activity and excess template/primer allows analysis of the length of extension of the primer with minimal chance for re-initia-

## 13

tion. Thus, analysis of product size by polyacrylamide/urea gel measures primer extension as a unit event, or processivity of the polymerase (trials 1 and 2).

Trial 3 is based on a new approach. We reasoned that it would be possible to measure processivity under conditions of PCR. With limiting enzyme concentration and excess primer/template concentration, the probability of re-initiation on a partially extended primer in PCR cycles is very low. Therefore, the length of the observed product (resulting from the complete extension of a primer through the opposing primer) is a measure of processivity. We found that 12 cycles results in sufficient yield to detect products with ethidium bromide on agarose gel. By varying the distance between primers we can determine a processivity range. AmpliTaq™, REM-T2, and REM-T3 have a processivity of at least 105 nucleotides, but less than 358 nucleotides. Stoffel Fragment, on the other hand has a processivity of less than 105 nucleotides.

FIG. 8 compares the ability of four polymerases to extend a primer 105 nucleotides (Lanes 1–4) or 358 nucleotides (Lanes 5–8) under PCR conditions of excess DNA template (0.02 pmol/10 µl of reaction) and primer (10 pmol/10 µl of reaction) and limited polymerase units (0.04 units of polymerase/10 µl reaction). PCR products are shown on a 3% NuSieve gel. AmpliTaq™ is in lanes 1 and 5, Stoffel Fragment is in lanes 2 and 6, REM-T2 in lanes 3 and 7, and REM-T3 in lanes 4 and 8. Marker lane has φX174/Hae III.

It is evident from an examination of FIGS. 6, 7, and 8 that REM-T3 (SEQ ID NO: 6) has a processivity equal to or better than AmpliTaq™, and much better than the Stoffel fragment. This result demonstrates that the full length polypeptide of the modified Taq enzyme confers superior processivity compared to the truncated peptide of the Stoffel enzyme.

## EXAMPLE 9

## Misincorporation Rate for Modified Taq DNA Polymerases

Information already published by Barnes, *Gene* 112, 29–35 (1992) indicates that Taq DNA polymerase which has

## 14

had the N-terminal region containing the 5' exonuclease domain removed has a diminished misincorporation rate. The information available indicates that such a modified Taq DNA polymerase has a two-fold lower misincorporation rate than native Taq DNA polymerase. Since the evidence presented by Barnes leads to the conclusion that the misincorporation by the Taq DNA polymerase is lowered in the absence of the exonuclease activity, we are motivated to measure the misincorporation rate of the modified Taq DNA polymerases described herein.

The assessment of misincorporation is done by several methodologies:

1. The methodology of Barnes uses a specially constructed plasmid with a flanking selectable marker, based on identification of lacZ as an indicator gene. Scoring for misincorporation in the lac gene is by the familiar blue/white test on an indicator dye (XGal). Testing for misincorporation is performed by inserting the plasmids into an indicator bacterial strain following PCR reactions in vitro.
2. The methodology of Tindall and Kunkel, *Biochemistry* 21, 6008–6013 (1988) monitors the fidelity of in vitro DNA synthesis using the lacZ gene for α complementation in a plasmid derived from M13 bacteriophage. Measurement of misincorporation is based on the blue/white test for lacZ function using an indicator dye in the plate. The plasmid derivative contains an open single-stranded gap region of 390 nucleotides. This construction allows measurement of the forward mutation rate, or the substantially lower reversion mutation rate for any specific misincorporation constructed. The results found by Kunkel and co-workers, indicate that the native Taq DNA polymerase has a base substitution error rate of approximately 1/9000 nucleotides polymerized.

The processivity of our modified Taq DNA polymerase is much higher than the processivity of the truncated proteolytic fragment, and since the DNA polymerase literature indicates that misincorporation correlates with re-initiation, our misincorporation rate is considerably improved relative to native Taq DNA polymerase.

What is claimed is:

## SEQUENCE LISTING

## ( 1 ) GENERAL INFORMATION:

( i i i ) NUMBER OF SEQUENCES: 15

## ( 2 ) INFORMATION FOR SEQ ID NO:1:

## ( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 2626 base pairs
- ( B ) TYPE: nucleic acid
- ( C ) STRANDEDNESS: single
- ( D ) TOPOLOGY: linear

( i i ) MOLECULE TYPE: cDNA

( i i i ) HYPOTHETICAL: NO

( i v ) ANTI-SENSE: NO

( v i ) ORIGINAL SOURCE:

( A ) ORGANISM: *Thermus aquaticus*

( i x ) FEATURE:

-continued

( A ) NAME/KEY: CDS  
 ( B ) LOCATION: 121..2619

( i x ) FEATURE:

( A ) NAME/KEY: mat\_peptide  
 ( B ) LOCATION: 121..2616

( i x ) FEATURE:

( A ) NAME/KEY: -  
 ( B ) LOCATION: 1..2625  
 ( D ) OTHER INFORMATION: /note="Native Taq DNA Polymerase  
 nucleotide sequence."

( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAGCTCAGAT	CTACCTGCCT	GAGGGCGTCC	GGTTCCAGCT	GGCCCTTCCC	GAGGGGGAGA	6 0										
GGGAGGGCGTT	TCTAAAAGCC	CTTCAGGACG	CTACCCGGGG	GCGGGTGGTG	GAAGGGTAAC	12 0										
ATG	AGG	GGG	ATG	CTG	CCC	CTC	TTT	GAG	CCC	AAG	GGC	CGG	GTC	CTC	CTG	16 8
Met	Arg	Gly	Met	Leu	Pro	Lec	Phe	Glu	Pro	Lys	Gly	Arg	Val	Leu	Lec	
1				5				10						15		
GTG	GAC	GGC	CAC	CAC	CTG	GCC	TAC	CGC	ACC	TTC	CAC	GCC	CTG	AAG	GGC	21 6
Val	Asp	Gly	His	His	Lec	Ala	Tyr	Arg	Thr	Phe	His	Ala	Leu	Lys	Gly	
				20				25					30			
CTC	ACC	ACC	AGC	CGG	GGG	GAG	CCG	GTG	CAG	GCG	GTC	TAC	GGC	TTC	GCC	26 4
Lec	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala	
				35				40				45				
AAG	AGC	CTC	CTC	AAG	GCC	CTC	AAG	GAG	GAC	GGG	GAC	GCG	GTG	ATC	GTG	31 2
Lys	Ser	Leu	Leu	Lys	Ala	Lec	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val	
				50				55				60				
GTC	TTT	GAC	GCC	AAG	GCC	CCC	TCC	TTC	CGC	CAC	GAG	GCC	TAC	GGG	GGG	36 0
Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala	Tyr	Gly	Gly	
				65				70				75		80		
TAC	AAG	GCG	GGC	CGG	GCC	CCC	ACG	CCG	GAG	GAC	TTT	CCC	CGG	CAA	CTC	40 8
Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Leu	
				85				90				95				
GCC	CTC	ATC	AAG	GAG	CTG	GTG	GAC	CTC	CTG	GGG	CTG	GCG	CGC	CTC	GAG	45 6
Ala	Lec	Ile	Lys	Glu	Lec	Val	Asp	Lec	Leu	Gly	Leu	Ala	Arg	Leu	Glu	
				100				105				110				
GTC	CCG	GGC	TAC	GAG	GCG	GAC	GAC	GTC	CTG	GCC	AGC	CTG	GCC	AAG	AAG	50 4
Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Leu	Ala	Lys	Lys	
				115				120				125				
GCG	GAA	AAG	GAG	GGC	TAC	GAG	GTC	CGC	ATC	CTC	ACC	GCC	GAC	AAA	GAC	55 2
Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys	Asp	
				130				135				140				
CTT	TAC	CAG	CTC	CTT	TCC	GAC	CGC	ATC	CAC	GTC	CTC	CAC	CCC	GAG	GGG	60 0
Leu	Tyr	Gln	Lec	Lec	Ser	Asp	Arg	Ile	His	Val	Lec	His	Pro	Glu	Gly	
				145				150				155		160		
TAC	CTC	ATC	ACC	CCG	GCC	TGG	CTT	TGG	GAA	AAG	TAC	GGC	CTG	AGG	CCC	64 8
Tyr	Lec	Ile	Thr	Pro	Ala	Trp	Lec	Trp	Glu	Lys	Tyr	Gly	Lec	Arg	Pro	
				165				170				175				
GAC	CAG	TGG	GCC	GAC	TAC	CGG	GCC	CTG	ACC	GGG	GAC	GAG	TCC	GAC	AAC	69 6
Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Scr	Asp	Asn	
				180				185				190				
CTT	CCC	GGG	GTC	AAG	GGC	ATC	GGG	GAG	AAG	ACG	GCG	AGG	AAG	CTT	CTG	74 4
Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Lec	Lec	
				195				200				205				
GAG	GAG	TGG	GGG	AGC	CTG	GAA	GCC	CTC	CTC	AAG	AAC	CTG	GAC	CGG	CTG	79 2
Glu	Glu	Trp	Gly	Scr	Lec	Glu	Ala	Lec	Lec	Lys	Asn	Leu	Asp	Arg	Lec	
				210				215				220				
AAG	CCC	GCC	ATC	CGG	GAG	AAG	ATC	CTG	GCC	CAC	ATG	GAC	GAT	CTG	AAG	84 0
Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Lec	Ala	His	Met	Asp	Asp	Lec	Lys	
				225				230				235		240		

-continued

CTC	TCC	TGG	GAC	CTG	GCC	AAG	GTG	CGC	ACC	GAC	CTG	CCC	CTG	GAG	GTG		888
Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Glu	Val		
			245					250						255			
GAC	TTC	GCC	AAA	AGG	CGG	GAG	CCC	GAC	CGG	GAG	AGG	CTT	AGG	GCC	TTT		936
Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala	Phe		
			260				265					270					
CTG	GAG	AGG	CTT	GAG	TTT	GGC	AGC	CTC	CTC	CAC	GAG	TTC	GGC	CTT	CTG		984
Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Leu	Leu	His	Glu	Phe	Gly	Leu	Leu		
			275			280					285						
GAA	AGC	CCC	AAG	GCC	CTG	GAG	GAG	GCC	CCC	TGG	CCC	CCG	CCG	GAA	GGG		1032
Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu	Gly		
			290			295				300							
GCC	TTC	GTG	GGC	TTT	GTG	CTT	TCC	CGC	AAG	GAG	CCC	ATG	TGG	GCC	GAT		1080
Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	Asp		
			305			310			315					320			
CTT	CTG	GCC	CTG	GCC	GCC	GCC	AGG	GGG	GGC	CGG	GTC	CAC	CGG	GCC	CCC		1128
Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro		
			325			330						335					
GAG	CCT	TAT	AAA	GCC	CTC	AGG	GAC	CTG	AAG	GAG	GCG	CGG	GGG	CTT	CTC		1176
Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu		
			340			345						350					
GCC	AAA	GAC	CTG	AGC	GTT	CTG	GCC	CTG	AGG	GAA	GGC	CTT	GGC	CTC	CCG		1224
Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro		
			355			360					365						
CCC	GGC	GAC	GAC	CCC	ATG	CTC	CTC	GCC	TAC	CTC	CTG	GAC	CCT	TCC	AAC		1272
Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn		
			370			375					380						
ACC	ACC	CCC	GAG	GGG	GTG	GCC	CGG	CGC	TAC	GGC	GGG	GAG	TGG	ACG	GAG		1320
Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Gl	Trp	Thr	Glu		
			385			390				395				400			
GAG	GCG	GGG	GAG	CGG	GCC	GCC	CTT	TCC	GAG	AGG	CTC	TTC	GCC	AAC	CTG		1368
Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu		
			405			410						415					
TGG	GGG	AGG	CTT	GAG	GGG	GAG	GAG	AGG	CTC	CTT	TGG	CTT	TAC	CGG	GAG		1416
Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu		
			420			425						430					
GTG	GAG	AGG	CCC	CTT	TCC	GCT	GTC	CTG	GCC	CAC	ATG	GAG	GCC	ACG	GGG		1464
Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly		
			435			440					445						
GTG	CGC	CTG	GAC	GTG	GCC	TAT	CTC	AGG	GCC	TTG	TCC	CTG	GAG	GTG	GCC		1512
Val	Arg	Leu	Asp	Val	Ala	Tyr	Lcu	Arg	Ala	Leu	Ser	Lcu	Glu	Val	Ala		
			450			455					460						
GAG	GAG	ATC	GCC	CGC	CTC	GAG	GCC	GAG	GTC	TTC	CGC	CTG	GCC	GGC	CAC		1560
Glu	Glu	Ile	Ala	Arg	Lcu	Glu	Ala	Glu	Val	Phe	Arg	Lcu	Ala	Gly	His		
			465			470			475					480			
CCC	TTC	AAC	CTC	AAC	TCC	CGG	GAC	CAG	CTG	GAA	AGG	GTC	CTC	TTT	GAC		1608
Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Lcu	Phe	Asp		
			485			490						495					
GAG	CTA	GGG	CTT	CCC	GCC	ATC	GTC	AAG	ACG	GAG	AAG	ACC	GGC	AAG	CGC		1656
Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys	Arg		
			500			505						510					
TCC	ACC	AGC	GCC	GCC	GTC	CTG	GAG	GCC	CTC	CGC	GAG	GCC	CAC	CCC	ATC		1704
Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile		
			515			520						525					
GTG	GAG	AAG	ATC	CTG	CAG	TAC	CGG	GAG	CTC	ACC	AAG	CTG	AAG	AGC	ACC		1752
Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Lys	Ser	Thr			
			530			535					540						
TAC	ATT	GAC	CCC	TTG	CCG	GAC	CTC	ATC	CAC	CCC	AGG	ACG	GGC	CGC	CTC		1800
Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Lcu	Ile	His	Pro	Arg	Thr	Gly	Arg	Lcu		
			545			550					555				560		

-continued

CAC	ACC	CGC	TTC	AAC	CAG	ACG	GCC	ACG	GCC	ACG	GCC	AGG	CTA	AGT	AGC		1848
His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser		
					565				570					575			
TCC	GAT	CCC	AAC	CTC	CAG	AAC	ATC	CCC	GTC	CGC	ACC	CCG	CTT	GGG	CAG		1896
Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln		
					580			585			590						
AGG	ATC	CGC	CGG	GCC	TTC	ATC	GCC	GAG	GAG	GGG	TGG	CTA	TTG	GTG	GCC		1944
Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala		
					595			600			605						
CTG	GAC	TAT	AGC	CAG	ATA	GAG	CTC	AGG	GTG	CTG	GCC	CAC	CTC	TCC	GGC		1992
Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly		
					610			615			620						
GAC	GAG	AAC	CTG	ATC	CGG	GTC	TTC	CAG	GAG	GGG	CGG	GAC	ATC	CAC	ACG		2040
Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr		
					625			630			635				640		
GAG	ACC	GCC	AGC	TGG	ATG	TTC	GGC	GTC	CCC	CGG	GAG	GCC	GTG	GAC	CCC		2088
Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro		
					645			650			655						
CTG	ATG	CGC	CGG	GCG	GCC	AAG	ACC	ATC	AAC	TTC	GGG	GTC	CTC	TAC	GGC		2136
Leu	Met	Arg	Arg	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly		
					660			665			670						
ATG	TCG	GCC	CAC	CGC	CTC	TCC	CAG	GAG	CTA	GCC	ATC	CCT	TAC	GAG	GAG		2184
Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu	Glu		
					675			680			685						
GCC	CAG	GCC	TTC	ATT	GAG	CGC	TAC	TTT	CAG	AGC	TTC	CCC	AAG	GTG	CGG		2232
Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val	Arg		
					690			695			700						
GCC	TGG	ATT	GAG	AAG	ACC	CTG	GAG	GAG	GGC	AGG	AGG	CGG	GGG	TAC	GTG		2280
Ala	Trp	Ile	Glu	Lys	Thr	Leu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr	Val		
					705			710			715				720		
GAG	ACC	CTC	TTC	GGC	CGC	CGC	TAC	GTC	CCA	GAC	CTA	GAG	GCC	CGG		2328	
Glu	Thr	Leu	Phe	Gly	Arg	Arg	Arg	Tyr	Val	Pro	Asp	Leu	Glu	Ala	Arg		
					725			730			735						
GTG	AAG	AGC	GTG	CGG	GAG	GCG	GCC	GAG	CGC	ATG	GCC	TTC	AAC	ATG	CCC		2376
Val	Lys	Ser	Val	Arg	Glu	Ala	Ala	Glu	Arg	Met	Ala	Phe	Asn	Met	Pro		
					740			745			750						
GTC	CAG	GGC	ACC	GCC	GCC	GAC	CTC	ATG	AAG	CTG	GCT	ATG	GTG	AAG	CTC		2424
Val	Gln	Gly	Thr	Ala	Ala	Asp	Leu	Met	Lys	Leu	Ala	Met	Val	Lys	Leu		
					755			760			765						
TTC	CCC	AGG	CTG	GAG	GAA	ATG	GGG	GCC	AGG	ATG	CTC	CTT	CAG	GTC	CAC		2472
Phc	Pro	Arg	Leu	Glu	Glu	Met	Gly	Ala	Arg	Met	Lcu	Leu	Gln	Val	His		
					770			775			780						
GAC	GAG	CTG	GTC	CTC	GAG	GCC	CCA	AAA	GAG	AGG	GCG	GAG	GCC	GTG	GCC		2520
Asp	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val	Ala		
					785			790			795				800		
CGG	CTG	GCC	AAG	GAG	GTC	ATG	GAG	GGG	GTG	TAT	CCC	CTG	GCC	GTG	CCC		2568
Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val	Pro		
					805			810			815						
CTG	GAG	GTG	GAG	GTG	GGG	ATA	GGG	GAG	GAC	TGG	CTC	TCC	GCC	AAG	GAG		2616
Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Lcu	Ser	Ala	Lys	Glu		
					820			825			830						
TGATACCA																2626	

( 2 ) INFORMATION FOR SEQ ID NO:2:

## ( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 832 amino acids
- ( B ) TYPE: amino acid
- ( D ) TOPOLOGY: linear

-continued

( i i ) MOLECULE TYPE: protein

( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Arg	Gly	Met	Lcu	Pro	Lcu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Lcu	Lcu
1				5				10						15	
Val	Asp	Gly	His	His	Lcu	Ala	Tyr	Arg	Thr	Phe	His	Ala	Lcu	Lys	Gly
			20					25					30		
Lcu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala
			35			40						45			
Lys	Ser	Lcu	Lcu	Lys	Ala	Lcu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val
				50		55					60				
Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala	Tyr	Gly	Gly
	65			70					75					80	
Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Lcu
			85					90					95		
Ala	Lcu	Ile	Lys	Glu	Lcu	Val	Asp	Lcu	Lcu	Gly	Lcu	Ala	Arg	Lcu	Glu
			100					105					110		
Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Lcu	Ala	Lys	Lys
	115		.			120						125			
Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Lcu	Thr	Ala	Asp	Lys	Asp
	130				135						140				
Lcu	Tyr	Gln	Lcu	Lcu	Ser	Asp	Arg	Ile	His	Val	Lcu	His	Pro	Glu	Gly
	145			150					155					160	
Tyr	Lcu	Ile	Thr	Pro	Ala	Trp	Lcu	Trp	Glu	Lys	Tyr	Gly	Lcu	Arg	Pro
	165							170					175		
Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Lcu	Thr	Gly	Asp	Glu	Ser	Asp	Asn
	180							185					190		
Lcu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Lcu	Lcu
	195					200						205			
Glu	Glu	Trp	Gly	Ser	Lcu	Glu	Ala	Lcu	Lcu	Lys	Asn	Lcu	Asp	Arg	Lcu
	210				215						220				
Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Lcu	Ala	His	Mct	Asp	Asp	Lcu	Lys
	225			230						235				240	
Lcu	Ser	Trp	Asp	Lcu	Ala	Lys	Val	Arg	Thr	Asp	Lcu	Pro	Lcu	Glu	Val
	245							250					255		
Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Lcu	Arg	Ala	Phe
	260					265						270			
Lcu	Glu	Arg	Lcu	Glu	Phe	Gly	Ser	Lcu	Lcu	His	Glu	Phe	Gly	Lcu	Lcu
	275					280						285			
Glu	Ser	Pro	Lys	Ala	Lcu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu	Gly
	290				295						300				
Ala	Phe	Val	Gly	Phe	Val	Lcu	Ser	Arg	Lys	Glu	Pro	Mct	Trp	Ala	Asp
	305			310									320		
Lcu	Lcu	Ala	Lcu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro
	325							330					335		
Glu	Pro	Tyr	Lys	Ala	Lcu	Arg	Asp	Lcu	Lys	Glu	Ala	Arg	Gly	Lcu	Lcu
	340						345						350		
Ala	Lys	Asp	Lcu	Ser	Val	Lcu	Ala	Lcu	Arg	Glu	Gly	Lcu	Gly	Lcu	Pro
	355				360							365			
Pro	Gly	Asp	Asp	Pro	Mct	Lcu	Lcu	Ala	Tyr	Lcu	Lcu	Asp	Pro	Ser	Asn
	370				375							380			
Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu
	385			390									395		400

5,474,920

**23****24**

-continued

Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu
			405						410					415	
Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu
			420					425					430		
Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly
			435				440				445				
Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala
			450			455				460					
Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His
			465			470				475				480	
Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp
			485					490					495		
Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys	Arg
			500					505					510		
Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile
			515				520					525			
Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr
			530			535				540					
Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu
			545			550			555				560		
His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser
			565					570					575		
Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln
			580					585					590		
Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala
			595				600					605			
Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly
			610			615				620					
Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr
			625			630			635				640		
Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro
			645					650					655		
Leu	Met	Arg	Arg	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly
			660				665					670			
Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu	Glu
			675				680					685			
Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val	Arg
			690			695					700				
Ala	Trp	Ile	Glu	Lys	Thr	Leu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr	Val
			705			710			715				720		
Glu	Thr	Leu	Phe	Gly	Arg	Arg	Tyr	Val	Pro	Asp	Leu	Glu	Ala	Arg	
			725					730					735		
Val	Lys	Ser	Val	Arg	Glu	Ala	Ala	Glu	Arg	Met	Ala	Phe	Asn	Met	Pro
			740					745					750		
Val	Gln	Gly	Thr	Ala	Ala	Asp	Leu	Met	Lys	Leu	Ala	Met	Val	Lys	Leu
			755				760					765			
Phe	Pro	Arg	Leu	Glu	Glu	Met	Gly	Ala	Arg	Met	Leu	Leu	Gln	Val	His
			770			775					780				
Asp	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val	Ala
			785			790			795				800		
Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val	Pro
			805						810				815		
Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Leu	Ser	Ala	Lys	Glu

5,474,920

**25**

**26**

-continued

8 2 0

8 2 5

8 3 0

( 2 ) INFORMATION FOR SEQ ID NO:3:

( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 2626 base pairs
- ( B ) TYPE: nucleic acid
- ( C ) STRANDEDNESS: single
- ( D ) TOPOLOGY: linear

( i i ) MOLECULE TYPE: DNA (genomic)

( i i i ) HYPOTHETICAL: NO

( i v ) ANTI-SENSE: NO

( v i ) ORIGINAL SOURCE:

- ( A ) ORGANISM: *Thermus aquaticus*

( i x ) FEATURE:

- ( A ) NAME/KEY: mutation
- ( B ) LOCATION: replace(89, "g")
- ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 89 of the native Taq DNA polymerase nucleotide sequence of C to G."

( i x ) FEATURE:

- ( A ) NAME/KEY: mutation
- ( B ) LOCATION: replace(934, "a")
- ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 934 of the native Taq DNA polymerase nucleotide sequence of T to A. This results in an amino acid change of Phe to Ile."

( i x ) FEATURE:

- ( A ) NAME/KEY: mutation
- ( B ) LOCATION: replace(962, "c")
- ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 962 of the native Taq DNA polymerase nucleotide sequence of T to C. This results in an amino acid change of Leu to Pro."

( i x ) FEATURE:

- ( A ) NAME/KEY: mutation
- ( B ) LOCATION: replace(2535, "a")
- ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 2535 of the native Taq DNA polymerase nucleotide sequence of G to A. This mutation is conservative."

( i x ) FEATURE:

- ( A ) NAME/KEY: CDS
- ( B ) LOCATION: 121..2619

( i x ) FEATURE:

- ( A ) NAME/KEY: mat\_peptide
- ( B ) LOCATION: 121..2616

( i x ) FEATURE:

- ( A ) NAME/KEY: -
- ( B ) LOCATION: 1..2619
- ( D ) OTHER INFORMATION: /note="pLSMS"

( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AAGCTCAGAT	CTACCTGCCT	GAGGGCGTCC	GGTTCCAGCT	GGCCCTTCCC	GAGGGGGAGA	6 0										
GGGAGGCGTT	TCTAAAAGCC	CTTCAGGAGG	CTACCCGGGG	GCGGGTGGTG	GAAGGGTAAC	1 2 0										
ATG	AGG	GGG	ATG	CTG	CCC	CTC	TTT	GAG	CCC	AAG	GGC	CGG	GTC	CTC	CTG	1 6 8
Met	Arg	Gly	Met	Leu	Pro	Leu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Leu	Leu	
1				5					1 0					1 5		
GTG	GAC	GGC	CAC	CAC	CTG	GCC	TAC	CGC	ACC	TTC	CAC	GCC	CTG	AAG	GGC	2 1 6
Val	Asp	Gly	His	His	Leu	Ala	Tyr	Arg	Thr	Phc	His	Ala	Leu	Lys	Gly	
					2 0				2 5				3 0			
CTC	ACC	ACC	AGC	CGG	GGG	GAG	CCG	GTG	CAG	GCG	GTC	TAC	GGC	TTC	GCC	2 6 4

-continued

Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala
							35					45			
AAG	AGC	CTC	CTC	AAG	GCC	CTC	AAG	GAG	GAC	GGG	GAC	GCG	GTG	ATC	GTG
Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val
							50				60				
GTC	TTT	GAC	GCC	AAG	GCC	CCC	TCC	TTC	CGC	CAC	GAG	GCC	TAC	GGG	GGG
Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Gl	Ala	Tyr	Gly	Gly
						65				75				80	
TAC	AAG	GCG	GGC	CGG	GCC	CCC	ACG	CCG	GAG	GAC	TTT	CCC	CGG	CAA	CTC
Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Leu
						85			90				95		
GCC	CTC	ATC	AAG	GAG	CTG	GTG	GAC	CTC	CTG	GGG	CTG	GCG	CGC	CTC	GAG
Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Leu	Leu	Gly	Leu	Ala	Arg	Leu	Glu
						100			105				110		
GTC	CCG	GGC	TAC	GAG	GCG	GAC	GAC	GTC	CTG	GCC	AGC	CTG	GCC	AAG	AAG
Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Leu	Ala	Lys	Lys
						115			120			125			
GCG	GAA	AAG	GAG	GGC	TAC	GAG	GTC	CGC	ATC	CTC	ACC	GCC	GAC	AAA	GAC
Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys	Asp
						130			135			140			
CTT	TAC	CAG	CTC	CTT	TCC	GAC	CGC	ATC	CAC	GTC	CTC	CAC	CCC	GAG	GGG
Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Gl	Gly
						145			150			155			160
TAC	CTC	ATC	ACC	CCG	GCC	TGG	CTT	TGG	GAA	AAG	TAC	GGC	CTG	AGG	CCC
Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg	Pro
						165			170			175			
GAC	CAG	TGG	GCC	GAC	TAC	CGG	GCC	CTG	ACC	GGG	GAC	GAG	TCC	GAC	AAC
Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Gl	Ser	Asp	Asn
						180			185			190			
CTT	CCC	GGG	GTC	AAG	GGC	ATC	GGG	GAG	AAG	ACG	GCG	AGG	AAG	CTT	CTG
Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Gl	Lys	Thr	Ala	Arg	Lys	Leu	Leu
						195			200			205			
GAG	GAG	TGG	GGG	AGC	CTG	GAA	GCC	CTC	CTC	AAG	AAC	CTG	GAC	CGG	CTG
Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Leu	Lys	Asn	Leu	Asp	Arg	Leu
						210			215			220			
AAG	CCC	GCC	ATC	CGG	GAG	AAG	ATC	CTG	GCC	CAC	ATG	GAC	GAT	CTG	AAG
Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Leu	Ala	His	Met	Asp	Asp	Leu	Lys
						225			230			235			240
CTC	TCC	TGG	GAC	CTG	GCC	AAG	GTG	CGC	ACC	GAC	CTG	CCC	CTG	GAG	GTG
Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Gl	Val
						245			250			255			
GAC	TTC	GCC	AAA	AGG	CGG	GAG	CCC	GAC	CGG	GAG	AGG	CTT	AGG	GCC	ATT
Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala	Ile
						260			265			270			
CTG	GAG	AGG	CTT	GAG	TTT	GGC	AGC	CCC	CTC	CAC	GAG	TTC	GGC	CTT	CTG
Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Pro	Leu	His	Glu	Ph	Gly	Leu	Leu
						275			280			285			
GAA	AGC	CCC	AAG	GCC	CTG	GAG	GAG	GCC	CCC	TGG	CCC	CCG	CCG	GAA	GGG
Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu	Gly
						290			295			300			
GCC	TTC	GTG	GGC	TTT	GTG	CTT	TCC	CGC	AAG	GAG	CCC	ATG	TGG	GCC	GAT
Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	Asp
						305			310			315			320
CTT	CTG	GCC	CTG	GCC	GCC	AGG	GGG	GGC	CGG	GTC	CAC	CGG	GCC	CCC	
Leu	Leu	Ala	Leu	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro	
						325			330			335			
GAG	CCT	TAT	AAA	GCC	CTC	AGG	GAC	CTG	AAG	GAG	GCG	CGG	GGG	CTT	CTC
Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu
						340			345			350			

-continued

GCC	AAA	GAC	CTG	AGC	GTT	CTG	GCC	CTG	AGG	GAA	GGC	CTT	GGC	CTC	CCG		1 2 2 4
Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro		
			3 5 5				3 6 0					3 6 5					
CCC	GGC	GAC	GAC	CCC	ATG	CTC	CTC	GCC	TAC	CTC	CTG	GAC	CCT	TCC	AAC		1 2 7 2
Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn		
	3 7 0				3 7 5						3 8 0						
ACC	ACC	CCC	GAG	GGG	GTG	GCC	CGG	CGC	TAC	GGC	GGG	GAG	TGG	ACG	GAG		1 3 2 0
Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu		
			3 8 5		3 9 0					3 9 5					4 0 0		
GAG	GCG	GGG	GAG	CGG	GCC	GCC	CTT	TCC	GAG	AGG	CTC	TTC	GCC	AAC	CTG		1 3 6 8
Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Lcu		
			4 0 5					4 1 0					4 1 5				
TGG	GGG	AGG	CTT	GAG	GGG	GAG	GAG	AGG	CTC	CTT	TGG	CTT	TAC	CGG	GAG		1 4 1 6
Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu		
			4 2 0				4 2 5					4 3 0					
GTG	GAG	AGG	CCC	CTT	TCC	GCT	GTC	CTG	GCC	CAC	ATG	GAG	GCC	ACG	GGG		1 4 6 4
Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly		
			4 3 5			4 4 0					4 4 5						
GTG	CGC	CTG	GAC	GTG	GCC	TAT	CTC	AGG	GCC	TTG	TCC	CTG	GAG	GTG	GCC		1 5 1 2
Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala		
			4 5 0			4 5 5				4 6 0							
GAG	GAG	ATC	GCC	CGC	CTC	GAG	GCC	GAG	GTC	TTC	CGC	CTG	GCC	GGC	CAC		1 5 6 0
Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His		
			4 6 5			4 7 0			4 7 5					4 8 0			
CCC	TTC	AAC	CTC	AAC	TCC	CGG	GAC	CAG	CTG	GAA	AGG	GTC	CTC	TTT	GAC		1 6 0 8
Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp		
				4 8 5				4 9 0					4 9 5				
GAG	CTA	GGG	CTT	CCC	GCC	ATC	GTC	AAG	ACG	GAG	AAG	ACC	GGC	AAG	CGC		1 6 5 6
Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys	Arg		
			5 0 0				5 0 5					5 1 0					
TCC	ACC	AGC	GCC	GCC	GTC	CTG	GAG	GCC	CTC	CGC	GAG	GCC	CAC	CCC	ATC		1 7 0 4
Ser	Thr	Ser	Ala	Ala	Val	Lcu	Glu	Ala	Lcu	Arg	Glu	Ala	His	Pro	Ile		
			5 1 5			5 2 0				5 2 5							
GTG	GAG	AAG	ATC	CTG	CAG	TAC	CGG	GAG	CTC	ACC	AAG	CTG	AAG	AGC	ACC		1 7 5 2
Val	Glu	Lys	Ile	Lcu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr		
			5 3 0			5 3 5				5 4 0							
TAC	ATT	GAC	CCC	TTG	CCG	GAC	CTC	ATC	CAC	CCC	AGG	ACG	GGC	CGC	CTC		1 8 0 0
Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Lcu	Ile	His	Pro	Arg	Thr	Gly	Arg	Lcu		
	5 4 5			5 5 0				5 5 5					5 6 0				
CAC	ACC	CGC	TTC	AAC	CAG	ACG	GCC	ACG	GCC	ACG	GGC	AGG	CTA	AGT	AGC		1 8 4 8
His	Thr	Arg	Phc	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Lcu	Ser	Ser		
			5 6 5				5 7 0					5 7 5					
TCC	GAT	CCC	AAC	CTC	CAG	AAC	ATC	CCC	GTC	CGC	ACC	CCG	CTT	GGG	CAG		1 8 9 6
Ser	Asp	Pro	Asn	Lcu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln		
			5 8 0				5 8 5					5 9 0					
AGG	ATC	CGC	CGG	GCC	TTC	ATC	GCC	GAG	GAG	GGG	TGG	CTA	TTG	GTG	GCC		1 9 4 4
Arg	Ile	Arg	Arg	Ala	Phc	Ile	Ala	Glu	Glu	Gly	Trp	Lcu	Leu	Val	Ala		
			5 9 5			6 0 0				6 0 5							
CTG	GAC	TAT	AGC	CAG	ATA	GAG	CTC	AGG	GTG	CTG	GCC	CAC	CTC	TCC	GGC		1 9 9 2
Lcu	Asp	Tyr	Ser	Gln	Ile	Glu	Lcu	Arg	Val	Lcu	Ala	His	Leu	Ser	Gly		
			6 1 0			6 1 5				6 2 0							
GAC	GAG	AAC	CTG	ATC	CGG	GTC	TTC	CAG	GAG	GGG	CGG	GAC	ATC	CAC	ACG		2 0 4 0
Asp	Glu	Asn	Leu	Ile	Arg	Val	Phc	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr		
	6 2 5				6 3 0				6 3 5					6 4 0			
GAG	ACC	GCC	AGC	TGG	ATG	TTC	GTC	CCC	CGG	GAG	GCC	GTG	GAC	CCC			2 0 8 8
Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro		
				6 4 5				6 5 0					6 5 5				
CTG	ATG	CGC	CGG	GCG	GCC	AAG	ACC	ATC	AAC	TTC	GGG	GTC	CTC	TAC	GGC		2 1 3 6
Lcu	Met	Arg	Arg	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly		
			6 6 0				6 6 5					6 7 0					

5,474,920

31

32

-continued

( 2 ) INFORMATION FOR SEQ ID NO:4:

( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 832 amino acids
- ( B ) TYPE: amino acid
- ( D ) TOPOLOGY: linear

( i i ) MOLECULE TYPE: protein

( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:4:

-continued

Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys	Asp	
130						135					140					
Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu	Gly	
145					150					155					160	
Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg	Pro	
				165					170						175	
Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Ser	Asp	Asn	
			180					185							190	
Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu	Leu	
			195				200					205				
Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Leu	Lys	Asn	Leu	Asp	Arg	Leu	
					210	215					220					
Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Leu	Ala	His	Met	Asp	Asp	Leu	Lys	
					225	230				235					240	
Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Glu	Val	
				245				250							255	
Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala	Ile	
			260					265							270	
Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Pro	Leu	His	Glu	Phe	Gly	Leu	Leu	
			275				280					285				
Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu	Gly	
					290	295				300						
Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	Asp	
					305	310				315					320	
Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro	
				325				330							335	
Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu	
			340					345					350			
Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro	
			355				360					365				
Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn	
				370		375				380						
Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu	
					385	390				395					400	
Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu	
				405					410						415	
Trp	Gly	Arg	Leu	Glu	Gly	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu		
			420				425					430				
Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly	
			435				440					445				
Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala	
			450			455					460					
Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His	
				465	470					475					480	
Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp	
				485					490					495		
Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys	Arg	
			500					505					510			
Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile	
			515			520					525					
Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr	
			530			535					540					
Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu	

5,474,920

**35****36**

-continued

5 4 5	5 5 0	5 5 5	5 6 0
H i s   T h r   A r g   P h e   A s n   G l n   T h r   A l a   T h r   A l a   T h r   G l y   A r g   L e u   S c r   S e r			
5 6 5		5 7 0	5 7 5
S c r   A s p   P r o   A s n   L e u   G l n   A s n   I l e   P r o   V a l   A r g   T h r   P r o   L e u   G l y   G l n			
5 8 0	5 8 5	5 9 0	
A r g   I l e   A r g   A r g   A l a   P h e   I l e   A l a   G l u   G l u   G l y   T r p   L e u   L e u   V a l   A l a			
5 9 5	6 0 0	6 0 5	
L e u   A s p   T y r   S c r   G l n   I l e   G l u   L e u   A r g   V a l   L e u   A l a   H i s   L e u   S c r   G l y			
6 1 0	6 1 5	6 2 0	
A s p   G l u   A s n   L e u   I l e   A r g   V a l   P h e   G l n   G l u   G l y   A r g   A s p   I l e   H i s   T h r			
6 2 5	6 3 0	6 3 5	6 4 0
G l u   T h r   A l a   S e r   T r p   M e t   P h e   G l y   V a l   P r o   A r g   G l u   A l a   V a l   A s p   P r o			
6 4 5	6 5 0	6 5 5	
L e u   M e t   A r g   A r g   A l a   A l a   L y s   T h r   I l e   A s n   P h e   G l y   V a l   L e u   T y r   G l y			
6 6 0	6 6 5	6 7 0	
M e t   S e r   A l a   H i s   A r g   L e u   S c r   G l n   G l u   L e u   A l a   I l e   P r o   T y r   G l u   G l u			
6 7 5	6 8 0	6 8 5	
A l a   G l n   A l a   P h e   I l e   G l u   A r g   T y r   P h e   G l n   S c r   P h e   P r o   L y s   V a l   A r g			
6 9 0	6 9 5	7 0 0	
A l a   T r p   I l e   G l u   L y s   T h r   L e u   G l u   G l u   G l y   A r g   A r g   A r g   G l y   T y r   V a l			
7 0 5	7 1 0	7 1 5	7 2 0
G l u   T h r   L e u   P h e   G l y   A r g   A r g   T y r   V a l   P r o   A s p   L e u   G l u   A l a   A r g			
7 2 5	7 3 0	7 3 5	
V a l   L y s   S c r   V a l   A r g   G l u   A l a   A l a   G l u   A r g   M e t   A l a   P h e   A s n   M e t   P r o			
7 4 0	7 4 5	7 5 0	
V a l   G l n   G l y   T h r   A l a   A l a   A s p   L e u   M e t   L y s   L e u   A l a   M e t   V a l   L y s   L e u			
7 5 5	7 6 0	7 6 5	
P h e   P r o   A r g   L e u   G l u   G l u   M e t   G l y   A l a   A r g   M e t   L e u   L e u   G l n   V a l   H i s			
7 7 0	7 7 5	7 8 0	
A s p   G l u   L e u   V a l   L e u   G l u   A l a   P r o   L y s   G l u   A r g   A l a   G l u   A l a   V a l   A l a			
7 8 5	7 9 0	7 9 5	8 0 0
A r g   L e u   A l a   L y s   G l u   V a l   M e t   G l u   G l y   V a l   T y r   P r o   L e u   A l a   V a l   P r o			
8 0 5	8 1 0	8 1 5	
L e u   G l u   V a l   G l u   V a l   G l y   I l e   G l y   G l u   A s p   T r p   L e u   S c r   A l a   L y s   G l u			
8 2 0	8 2 5	8 3 0	

( 2 ) INFORMATION FOR SEQ ID NO:5:

( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 2626 base pairs
- ( B ) TYPE: nucleic acid
- ( C ) STRANDEDNESS: single
- ( D ) TOPOLOGY: linear

( ii ) MOLECULE TYPE: DNA (genomic)

( iii ) HYPOTHETICAL: NO

( iv ) ANTI-SENSE: NO

( v i ) ORIGINAL SOURCE:

- ( A ) ORGANISM: *Thermus aquaticus*

( i x ) FEATURE:

- ( A ) NAME/KEY: mutation
- ( B ) LOCATION: replace(89, "g")
- ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 89 of the native Taq DNA polymerase nucleotide sequence of C to G."

( i x ) FEATURE:

-continued

( A ) NAME/KEY: mutation  
 ( B ) LOCATION: replace(934, "a")  
 ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 934 of the native Taq DNA polymerase nucleotide sequence of T to A. This results in an amino acid change of Phe to Ile."

( i x ) FEATURE:  
 ( A ) NAME/KEY: mutation  
 ( B ) LOCATION: replace(962, "c")  
 ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 962 of the native Taq DNA polymerase nucleotide sequence of T to C. This results in an amino acid change of Leu to Pro."

( i x ) FEATURE:  
 ( A ) NAME/KEY: mutation  
 ( B ) LOCATION: replace(2535, "a")  
 ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 2535 of the native Taq DNA polymerase nucleotide sequence of G to A. This mutation is conservative."

( i x ) FEATURE:  
 ( A ) NAME/KEY: mutation  
 ( B ) LOCATION: replace(193, "t")  
 ( D ) OTHER INFORMATION: /note="This mutation changes the nucleotide at position 193 of the native Taq DNA polymerase from C to T, resulting in an amino acid change of Arg to Cys."

( i x ) FEATURE:  
 ( A ) NAME/KEY: mutation  
 ( B ) LOCATION: replace(504, "a")  
 ( D ) OTHER INFORMATION: /note="This mutation changes the nucleotide at position 504 of the native Taq DNA polymerase from G to A, which is conservative in nature."

( i x ) FEATURE:  
 ( A ) NAME/KEY: CDS  
 ( B ) LOCATION: 121..2619

( i x ) FEATURE:  
 ( A ) NAME/KEY: mat\_peptide  
 ( B ) LOCATION: 121..2616

( i x ) FEATURE:  
 ( A ) NAME/KEY: -  
 ( B ) LOCATION: 1..2619  
 ( D ) OTHER INFORMATION: /note="pTarf3"

( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AAGCTCAGAT	CTACCTGCCT	GAGGGCGTCC	GGTTCCAGCT	GGCCCTTCCC	GAGGGGGAGA	6 0										
GGGAGGGCGTT	TCTAAAAGCC	CTTCAGGAGG	CTACCCGGGG	GCGGGTGGTG	GAAGGGTAAC	12 0										
ATG	AGG	GGG	ATG	CTG	CCC	CTC	TTT	GAG	CCC	AAG	GGC	CGG	GTC	CTC	CTG	16 8
Met	Arg	Gly	Met	Leu	Pro	Leu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Leu	Leu	
1				5					10					15		
GTG	GAC	GCG	CAC	CAC	CTG	GCC	TAC	TGC	ACC	TTC	CAC	GCC	CTG	AAG	GGC	21 6
Val	Asp	Gly	His	His	Leu	Ala	Tyr	Cys	Thr	Phe	His	Ala	Leu	Lys	Gly	
					20			25			30					
CTC	ACC	ACC	AGC	CGG	GGG	GAG	CCG	GTG	CAG	GCG	GTC	TAC	GGC	TTC	GCC	26 4
Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala	
					35			40			45					
AAG	AGC	CTC	CTC	AAG	GCC	CTC	AAG	GAG	GAC	GGG	GAC	GCG	GTG	ATC	GTG	31 2
Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val	
					50			55			60					
GTC	TTT	GAC	GCC	AAG	GCC	CCC	TCC	TTC	CGC	CAC	GAG	GCC	TAC	GGG	GGG	36 0
Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala	Tyr	Gly	Gly	
					65			70			75			80		
TAC	AAG	GCG	GGC	CGG	GCC	CCC	ACG	CCG	GAG	GAC	TTT	CCC	CGG	CAA	CTC	40 8
Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Leu	

-continued

-continued

Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu	
			4 0 5					4 1 0					4 1 5			
TGG	GGG	AGG	CTT	GAG	GGG	GAG	GAG	AGG	CTC	CTT	TGG	CTT	TAC	CGG	GAG	1 4 1 6
Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu	4 2 0
				4 2 5								4 3 0				
GTG	GAG	AGG	CCC	CTT	TCC	GCT	GTC	CTG	GCC	CAC	ATG	GAG	GCC	ACG	GGG	1 4 6 4
Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly	4 3 5
						4 4 0					4 4 5					
GTG	CGC	CTG	GAC	GTG	GCC	TAT	CTC	AGG	GCC	TTG	TCC	CTG	GAG	GTG	GCC	1 5 1 2
Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala	4 5 0
						4 5 5				4 6 0						
GAG	GAG	ATC	GCC	CGC	CTC	GAG	GCC	GAG	GTC	TTC	CGC	CTG	GCC	GGC	CAC	1 5 6 0
Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His	4 6 5
					4 7 0				4 7 5					4 8 0		
CCC	TTC	AAC	CTC	AAC	TCC	CGG	GAC	CAG	CTG	GAA	AGG	GTC	CTC	TTT	GAC	1 6 0 8
Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp	4 8 5
						4 9 0						4 9 5				
GAG	CTA	GGG	CTT	CCC	GCC	ATC	GGC	AAG	ACG	GAG	AAG	ACC	GGC	AAG	CGC	1 6 5 6
Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys	Arg	5 0 0
						5 0 5						5 1 0				
TCC	ACC	AGC	GCC	GCC	GTC	CTG	GAG	GCC	CTC	CGC	GAG	GCC	CAC	CCC	ATC	1 7 0 4
Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile	5 1 5
						5 2 0				5 2 5						
GTG	GAG	AAG	ATC	CTG	CAG	TAC	CGG	GAG	CTC	ACC	AAG	CTG	AAG	AGC	ACC	1 7 5 2
Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr	5 3 0
						5 3 5				5 4 0						
TAC	ATT	GAC	CCC	TTG	CCG	GAC	CTC	ATC	CAC	CCC	AGG	ACG	GGC	CGC	CTC	1 8 0 0
Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu	5 4 5
					5 5 0				5 5 5					5 6 0		
CAC	ACC	CGC	TTC	AAC	CAG	ACG	GCC	ACG	GCC	ACG	GGC	AGG	CTA	AGT	AGC	1 8 4 8
His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser	5 6 5
						5 7 0						5 7 5				
TCC	GAT	CCC	AAC	CTC	CAG	AAC	ATC	CCC	GTC	CGC	ACC	CCG	CTT	GGG	CAG	1 8 9 6
Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln	5 8 0
						5 8 5					5 9 0					
AGG	ATC	CGC	CGG	GCC	TTC	ATC	GCC	GAG	GAG	GGG	TGG	CTA	TTG	GTG	GCC	1 9 4 4
Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Lcu	Val	Ala	5 9 5
						6 0 0					6 0 5					
CTG	GAC	TAT	AGC	CAG	ATA	GAG	CTC	AGG	GTG	CTG	GCC	CAC	CTC	TCC	GGC	1 9 9 2
Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly	6 1 0
						6 1 5				6 2 0						
GAC	GAG	AAC	CTG	ATC	CGG	GTC	TTC	CAG	GAG	GGG	CGG	GAC	ATC	CAC	ACG	2 0 4 0
Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr	6 2 5
					6 3 0				6 3 5					6 4 0		
GAG	ACC	GCC	AGC	TGG	ATG	TTC	GGC	GTC	CCC	CGG	GAG	GCC	GTG	GAC	CCC	2 0 8 8
Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro	6 4 5
						6 5 0					6 5 5					
CTG	ATG	CGC	CGG	GCG	GCC	AAG	ACC	ATC	AAC	TTC	GGG	GTC	CTC	TAC	GGC	2 1 3 6
Leu	Met	Arg	Arg	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly	6 6 0
						6 6 5					6 7 0					
ATG	TCG	GCC	CAC	CGC	CTC	TCC	CAG	GAG	CTA	GCC	ATC	CCT	TAC	GAG	GAG	2 1 8 4
Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu	Glu	6 7 5
						6 8 0					6 8 5					
GCC	CAG	GCC	TTC	ATT	GAG	CGC	TAC	TTT	CAG	AGC	TTC	CCC	AAG	GTG	CGG	2 2 3 2
Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val	Arg	6 9 0
					6 9 5					7 0 0						
GCC	TGG	ATT	GAG	AAG	ACC	CTG	GAG	GAG	GGC	AGG	AGG	CGG	GGG	TAC	GTG	2 2 8 0
Ala	Trp	Ile	Glu	Lys	Thr	Leu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr	Val	7 0 5
					7 1 0				7 1 5					7 2 0		

-continued

GAG	ACC	CTC	TTC	GGC	CGC	CGC	CGC	TAC	GTG	CCA	GAC	CTA	GAG	GCC	CGG	2328
Glu	Thr	Leu	Phe	Gly	Arg	Arg	Arg	Tyr	Val	Pro	Asp	Leu	Glu	Ala	Arg	
				725					730					735		
GTG	AAG	AGC	GTG	CGG	GAG	GCG	GCC	GAG	CGC	ATG	GCC	TTC	AAC	ATG	CCC	2376
Val	Lys	Ser	Val	Arg	Glu	Ala	Ala	Glu	Arg	Met	Ala	Phe	Asn	Met	Pro	
				740				745				750				
GTC	CAG	GGC	ACC	GCC	GCC	GAC	CTC	ATG	AAG	CTG	GCT	ATG	GTG	AAG	CTC	2424
Val	Gln	Gly	Thr	Ala	Ala	Asp	Leu	Met	Lys	Leu	Ala	Met	Val	Lys	Leu	
				755			760				765					
TTC	CCC	AGG	CTG	GAG	GAA	ATG	GGG	GCC	AGG	ATG	CTC	CTT	CAG	GTC	CAC	2472
Phe	Pro	Arg	Leu	Glu	Glu	Met	Gly	Ala	Arg	Met	Lcu	Leu	Gln	Val	His	
				770			775			780						
GAC	GAG	CTG	GTC	CTC	GAG	GCC	CCA	AAA	GAG	AGG	GCG	GAG	GCC	GTG	GCC	2520
Asp	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val	Ala	
				785			790			795				800		
CGG	CTG	GCC	AAG	GAA	GTC	ATG	GAG	GGG	GTG	TAT	CCC	CTG	GCC	GTG	CCC	2568
Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val	Pro	
				805				810						815		
CTG	GAG	GTG	GAG	GTG	GGG	ATA	GGG	GAG	GAC	TGG	CTC	TCC	GCC	AAG	GAG	2616
Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Leu	Ser	Ala	Lys	Glu	
				820				825						830		

TGATACCAACC

2626

( 2 ) INFORMATION FOR SEQ ID NO:6:

## ( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 832 amino acids
- ( B ) TYPE: amino acid
- ( D ) TOPOLOGY: linear

( ii ) MOLECULE TYPE: protein

( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met	Arg	Gly	Met	Leu	Pro	Leu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Leu	Leu	
1				5					10					15		
Val	Asp	Gly	His	His	Leu	Ala	Tyr	Cys	Thr	Phe	His	Ala	Leu	Lys	Gly	
				20				25					30			
Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala	
				35			40					45				
Lys	Ser	Leu	Leu	Lys	Ala	Lcu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val	
				50			55				60					
Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala	Tyr	Gly	Gly	
	65				70				75				80			
Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Leu	
				85				90					95			
Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Lcu	Lys	Gly	Leu	Ala	Arg	Leu	Glu	
				100				105					110			
Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Lcu	Ala	Lys	Lys	
	115				120						125					
Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Lcu	Thr	Ala	Asp	Lys	Asp	
	130				135						140					
Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu	Gly	
	145				150					155				160		
Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg	Pro	
				165					170				175			
Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Lcu	Thr	Gly	Asp	Glu	Ser	Asp	Asn	
				180					185				190			
Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu	Leu	

5,474,920

45

46

-continued

	195	200	205
Glu	Glu	Trp	Gly
210	215		
Lys	Pro	Ala	Ile
225	Arg	Glu	Lys
	230		
Leu	Ser	Trp	Asp
		Lcu	Ala
		Lys	Val
	245		Arg
Asp	Phe	Ala	Lys
		Arg	Arg
	260	Glu	Pro
			Asp
			Arg
			Glu
			Arg
			Lcu
			Arg
			Ala
			Ile
Leu	Glu	Arg	Leu
275	Glu	Phe	Gly
		Ser	Pro
			Leu
			His
			Glu
			Phe
			Gly
			Leu
			Leu
Glu	Ser	Pro	Lys
290	Ala	Leu	Glu
			Glu
			Ala
			Pro
			Trp
			Pro
			Pro
			Pro
			Glu
			Gly
Ala	Phe	Val	Gly
305	Phe	Val	Val
		Leu	Ser
			Arg
			Lys
			Glu
			Pro
			Met
			Trp
			Ala
			Asp
Leu	Leu	Ala	Leu
325	Ala	Ala	Ala
			Arg
			Gly
			Gly
			Arg
			Val
			His
			Arg
			Ala
			Pro
Glu	Pro	Tyr	Lys
340	Ala	Leu	Arg
			Asp
			Leu
			Lys
			Glu
			Ala
			Arg
			Gly
			Leu
			Leu
Ala	Lys	Asp	Leu
355	Ser	Val	Leu
			Ala
			Leu
			Arg
			Glu
			Gly
			Leu
			Gly
			Leu
			Pro
Pro	Gly	Asp	Asp
370	Pro	Met	Leu
			Leu
			Ala
			Tyr
			Leu
			Leu
			Asp
			Pro
			Ser
			Asn
Glu	Ala	Gly	Glu
405	Arg	Ala	Ala
			Leu
			Ser
			Glu
			Arg
			Leu
			Phe
			Ala
			Asn
			Leu
Trp	Gly	Arg	Leu
420	Glu	Gly	Glu
			Glu
			Arg
			Leu
			Leu
			Trp
			Leu
			Tyr
			Arg
			Gly
Val	Glu	Arg	Pro
435	Leu	Scr	Ala
			Val
			Leu
			Ala
			His
			Met
			Glu
			Ala
			Thr
			Gly
Val	Arg	Leu	Asp
450	Val	Ala	Tyr
			Leu
			Arg
			Ala
			Leu
			Scr
			Leu
			Glu
			Val
			Ala
Glu	Glu	Ile	Ala
465	Arg	Leu	Glu
			Ala
			Glu
			Val
			Phe
			Arg
			Leu
			Ala
			Gly
			His
480			
Pro	Phe	Asn	Leu
485	Asn	Ser	Arg
			Asp
			Gln
			Lcu
			Glu
			Arg
			Val
			Leu
			Phe
			Asp
Glu	Leu	Gly	Lcu
500	Pro	Ala	Ile
			Gly
			Lys
			Thr
			Glu
			Lys
			Thr
			Gly
			Lys
			Arg
Ser	Thr	Ser	Ala
515	Ala	Ala	Val
			Leu
			Glu
			Ala
			Leu
			Arg
			Glu
			Ala
			His
			Pro
			Ile
Val	Glu	Lys	Ile
530	Leu	Gln	Tyr
			Arg
			Glu
			Leu
			Thr
			Lys
			Lcu
			Lys
			Ser
			Thr
Tyr	Ile	Asp	Pro
545	Leu	Pro	Asp
			Leu
			Ile
			His
			Pro
			Arg
			Gly
			Arg
			Leu
His	Thr	Arg	Phe
565	Asn	Gln	Thr
			Ala
			Thr
			Ala
			Thr
			Gly
			Arg
			Leu
			Scr
			Ser
Scr	Asp	Pro	Asn
580	Leu	Gln	Asn
			Ile
			Pro
			Val
			Arg
			Thr
			Pro
			Leu
			Gly
			Gln
Arg	Ile	Arg	Arg
595	Ala	Phe	Ile
			Ala
			Glu
			Glu
			Gly
			Trp
			Leu
			Leu
			Val
			Ala
Leu	Asp	Tyr	Ser
610	Gln	Ile	Glu
			Leu
			Arg
			Val
			Leu
			Ala
			His
			Leu
			Ser
			Gly

-continued

---

A s p	G l u	A s n	L c u	I l c	A r g	V a l	P h e	G l n	G l u	G l y	A r g	A s p	I l e	H i s	T h r
6 2 5					6 3 0				6 3 5						6 4 0
G l u	T h r	A l a	S e r	T r p	M e t	P h e	G l y	V a l	P r o	A r g	G l u	A l a	V a l	A s p	P r o
					6 4 5				6 5 0					6 5 5	
L c u	M e t	A r g	A r g	A l a	A l a	L y s	T h r	I l c	A s n	P h e	G l y	V a l	L c u	T y r	G l y
				6 6 0				6 6 5					6 7 0		
M e t	S e r	A l a	H i s	A r g	L c u	S e r	G l n	G l u	L c u	A l a	I l e	P r o	T y r	G l u	G l u
				6 7 5			6 8 0					6 8 5			
A l a	G l n	A l a	P h e	I l c	G l u	A r g	T y r	P h e	G l n	S e r	P h e	P r o	L y s	V a l	A r g
				6 9 0		6 9 5			7 0 0						
A l a	T r p	I l c	G l u	L y s	T h r	L c u	G l u	G l u	G l y	A r g	A r g	A r g	G l y	T y r	V a l
				7 0 5		7 1 0			7 1 5					7 2 0	
G l u	T h r	L c u	P h e	G l y	A r g	A r g	T y r	V a l	P r o	A s p	L c u	G l u	A l a	A r g	
				7 2 5				7 3 0				7 3 5			
V a l	L y s	S e r	V a l	A r g	G l u	A l a	A l a	G l u	A r g	M e t	A l a	P h e	A s n	M e t	P r o
			7 4 0					7 4 5					7 5 0		
V a l	G l n	G l y	T h r	A l a	A l a	A s p	L c u	M e t	L y s	L c u	A l a	M e t	V a l	L y s	L c u
			7 5 5				7 6 0					7 6 5			
P h e	P r o	A r g	L c u	G l u	G l u	M e t	G l y	A l a	A r g	M e t	L c u	L c u	G l n	V a l	H i s
			7 7 0			7 7 5					7 8 0				
A s p	G l u	L c u	V a l	L c u	G l u	A l a	P r o	L y s	G l u	A r g	A l a	G l u	A l a	V a l	A l a
			7 8 5		7 9 0				7 9 5					8 0 0	
A r g	L c u	A l a	L y s	G l u	V a l	M e t	G l u	G l y	V a l	T y r	P r o	L c u	A l a	V a l	P r o
			8 0 5					8 1 0					8 1 5		
L c u	G l u	V a l	G l u	V a l	G l y	I l c	G l y	G l u	A s p	T r p	L c u	S e r	A l a	L y s	G l u
			8 2 0					8 2 5					8 3 0		

---

## ( 2 ) INFORMATION FOR SEQ ID NO:7:

## ( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 2626 base pairs
- ( B ) TYPE: nucleic acid
- ( C ) STRANDEDNESS: single
- ( D ) TOPOLOGY: linear

( i i ) MOLECULE TYPE: DNA (genomic)

( i i i ) HYPOTHETICAL: NO

( i v ) ANTI-SENSE: NO

( v i ) ORIGINAL SOURCE:

( A ) ORGANISM: *Thermus aquaticus*

( i x ) FEATURE:

- ( A ) NAME/KEY: mutation
- ( B ) LOCATION: replace(89, "g")
- ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 89 of the native Taq DNA polymerase nucleotide sequence of C to G."

( i x ) FEATURE:

- ( A ) NAME/KEY: mutation
- ( B ) LOCATION: replace(934, "a")
- ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 934 of the native Taq DNA polymerase nucleotide sequence of T to A. This results in an amino acid change of Phe to Ile."

( i x ) FEATURE:

- ( A ) NAME/KEY: mutation
- ( B ) LOCATION: replace(962, "c")
- ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 962 of the native Taq DNA polymerase nucleotide sequence of T to C. This

-continued

results in an amino acid change of Lcu to Pro."

## ( i x ) FEATURE:

( A ) NAME/KEY: mutation  
 ( B ) LOCATION: replace(2535, "a")  
 ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 2535 of the native Taq DNA polymerase nucleotide sequence of G to A. This mutation is conservative."

## ( i x ) FEATURE:

( A ) NAME/KEY: mutation  
 ( B ) LOCATION: replace(341, "a")  
 ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 341 of the native Taq DNA polymerase nucleotide sequence of G to A. This mutation results in an amino acid change of Arg to His."

## ( i x ) FEATURE:

( A ) NAME/KEY: CDS  
 ( B ) LOCATION: 121..2619

## ( i x ) FEATURE:

( A ) NAME/KEY: mal\_peptide  
 ( B ) LOCATION: 121..2616

## ( i x ) FEATURE:

( A ) NAME/KEY: -  
 ( B ) LOCATION: 1..2619  
 ( D ) OTHER INFORMATION: /note="pTarf5"

## ( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AAGCTCAGAT	CTACCTGCCT	GAGGGCGTCC	GGTTCCAGCT	GGCCCTTCCC	GAGGGGGAGA	6 0										
GGGAGGGCGTT	TCTAAAAGCC	CTTCAGGAGG	CTACCCGGGG	GCGGGTGGTG	GAAGGGTAAC	1 2 0										
ATG	AGG	GGG	ATG	CTG	CCC	CTC	TTT	GAG	CCC	AAG	GGC	CGG	GTC	CTC	CTG	1 6 8
Met	Arg	Gly	Met	Lcu	Pro	Lcu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Lcu	Lcu	
1				5				1 0						1 5		
GTG	GAC	GGC	CAC	CAC	CTG	GCC	TAC	CGC	ACC	TTC	CAC	GCC	CTG	AAG	GGC	2 1 6
Val	Asp	Gly	His	His	Lcu	Ala	Tyr	Arg	Thr	Phe	His	Ala	Lcu	Lys	Gly	
2 0							2 5						3 0			
CTC	ACC	ACC	AGC	CGG	GGG	GAG	CCG	GTG	CAG	GCG	GTC	TAC	GGC	TTC	GCC	2 6 4
Lcu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala	
3 5							4 0					4 5				
AAG	AGC	CTC	CTC	AAG	GCC	CTC	AAG	GAG	GAC	GGG	GAC	GCG	GTG	ATC	GTG	3 1 2
Lys	Ser	Lcu	Lcu	Lys	Ala	Lcu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val	
5 0							5 5					6 0				
GTC	TTT	GAC	GCC	AAG	GCC	CCC	TCC	TTC	CAC	CAC	GAG	GCC	TAC	GGG	GGG	3 6 0
Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	His	His	Glu	Ala	Tyr	Gly	Gly	
6 5						7 0					7 5			8 0		
TAC	AAG	GCG	GGC	CGG	GCC	CCC	ACG	CCG	GAG	GAC	TTT	CCC	CGG	CAA	CTC	4 0 8
Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Lcu	
8 5								9 0					9 5			
GCC	CTC	ATC	AAG	GAG	CTG	GTG	GAC	CTC	CTG	GGG	CTG	GCG	CGC	CTC	GAG	4 5 6
Ala	Lcu	Ile	Lys	Glu	Lcu	Val	Asp	Lcu	Lcu	Gly	Lcu	Ala	Arg	Lcu	Glu	
1 0 0							1 0 5						1 1 0			
GTC	CCG	GGC	TAC	GAG	GCG	GAC	GAC	GTC	CTG	GCC	AGC	CTG	GCC	AAG	AAG	5 0 4
Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Lcu	Ala	Ser	Lcu	Ala	Lys	Lys	
1 1 5							1 2 0					1 2 5				
GCG	GAA	AAG	GAG	GGC	TAC	GAG	GTC	CGC	ATC	CTC	ACC	GCC	GAC	AAA	GAC	5 5 2
Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Lcu	Thr	Ala	Asp	Lys	Asp	
1 3 0							1 3 5					1 4 0				
CTT	TAC	CAG	CTC	CTT	TCC	GAC	CGC	ATC	CAC	GTC	CTC	CAC	CCC	GAG	GGG	6 0 0
Lcu	Tyr	Gin	Lcu	Lcu	Ser	Asp	Arg	Ile	His	Val	Lcu	His	Pro	Glu	Gly	
1 4 5						1 5 0					1 5 5			1 6 0		
TAC	CTC	ATC	ACC	CCG	GCC	TGG	CTT	TGG	GAA	AAG	TAC	GGC	CTG	AGG	CCC	6 4 8
Tyr	Lcu	Ile	Thr	Pro	Ala	Trp	Lcu	Trp	Glu	Lys	Tyr	Gly	Lcu	Arg	Pro	

-continued

	165	170	175	
GAC CAG TGG GCC GAC TAC CGG GCC CTG ACC GGG GAC GAG TCC GAC AAC				696
Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn	180	185	190	
CTT CCC GGG GTC AAG GGC ATC GGG GAG AAG ACG GCG AGG AAG CTT CTG				744
Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu	195	200	205	
GAG GAG TGG GGG AGC CTG GAA GCC CTC CTC AAG AAC CTG GAC CGG CTG				792
Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu	210	215	220	
AAG CCC GCC ATC CGG GAG AAG ATC CTG GCC CAC ATG GAC GAT CTG AAG				840
Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys	225	230	235	
CTC TCC TGG GAC CTG GCC AAG GTG CGC ACC GAC CTG CCC CTG GAG GTG				888
Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val	245	250	255	
GAC TTC GCC AAA AGG CGG GAG CCC GAC CGG GAG AGG CTT AGG GCC ATT				936
Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Ile	260	265	270	
CTG GAG AGG CTT GAG TTT GGC AGC CCC CTC CAC GAG TTC GGC CTT CTG				984
Leu Glu Arg Leu Glu Phe Gly Ser Pro Leu His Glu Phe Gly Leu Leu	275	280	285	
GAA AGC CCC AAG GCC CTG GAG GAG GCC CCC TGG CCC CCG CCG GAA GGG				1032
Glu Scr Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Glu	290	295	300	
GCC TTC GTG GGC TTT GTG CTT TCC CGC AAG GAG CCC ATG TGG GCC GAT				1080
Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp	305	310	315	
CTT CTG GCC CTG GCC GCC AGG GGG GGC CGG GTC CAC CGG GCC CCC				1128
Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro	325	330	335	
GAG CCT TAT AAA GCC CTC AGG GAC CTG AAG GAG GCG CGG GGG CTT CTC				1176
Glu Pro Tyr Lys Ala Leu Arg Asp Lcu Lys Glu Ala Arg Gly Lcu Leu	340	345	350	
GCC AAA GAC CTG AGC GTT CTG GCC CTG AGG GAA GGC CTT GGC CTC CCG				1224
Ala Lys Asp Lcu Scr Val Leu Ala Leu Arg Glu Gly Leu Gly Lcu Pro	355	360	365	
CCC GGC GAC GAC CCC ATG CTC CTC GCC TAC CTC CTG GAC CCT TCC AAC				1272
Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Lcu Asp Pro Scr Asn	370	375	380	
ACC ACC CCC GAG GGG GTG GCC CGG CGC TAC GGC GGG GAG TGG ACG GAG				1320
Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu	385	390	395	
400				
GAG GCG GGG GAG CGG GCC GGC CTT TCC GAG AGG CTC TTC GCC AAC CTG				1368
Glu Ala Gly Glu Arg Ala Ala Lcu Scr Glu Arg Lcu Phe Ala Asn Lcu	405	410	415	
TGG GGG AGG CTT GAG GGG GAG GAG AGG CTC CTT TGG CTT TAC CGG GAG				1416
Trp Gly Arg Lcu Glu Gly Glu Glu Arg Lcu Leu Trp Leu Tyr Arg Glu	420	425	430	
GTC GAG AGG CCC CTT TCC GCT GTC CTG GCC CAC ATG GAG GCC ACG GGG				1464
Val Glu Arg Pro Leu Scr Ala Val Lcu Ala His Met Glu Ala Thr Gly	435	440	445	
GTC CGC CTG GAC GTG GCC TAT CTC AGG GCC TTG TCC CTG GAG GTG GCC				1512
Val Arg Leu Asp Val Ala Tyr Lcu Arg Ala Leu Scr Lcu Glu Val Ala	450	455	460	
GAG GAG ATC GCC CGC CTC GAG GCC GAG GTC TTC CGC CTG GCC GGC CAC				1560
Glu Glu Ile Ala Arg Lcu Glu Ala Glu Val Phe Arg Lcu Ala Gly His	465	470	475	
480				
CCC TTC AAC CTC AAC TCC CGG GAC CAG CTG GAA AGG GTC CTC TTT GAC				1608

-continued

Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp	
				4 8 5					4 9 0					4 9 5		
GAG	CTA	GGG	CTT	CCC	GCC	ATC	GGC	AAG	ACG	GAG	AAG	ACC	GGC	AAG	CGC	1 6 5 6
Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys	Arg	
			5 0 0					5 0 5					5 1 0			
TCC	ACC	AGC	GCC	GCC	GTC	CTG	GAG	GCC	CTC	CGC	GAG	GCC	CAC	CCC	ATC	1 7 0 4
Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile	
			5 1 5				5 2 0				5 2 5					
GTG	GAG	AAG	ATC	CTG	CAG	TAC	CGG	GAG	CTC	ACC	AAG	CTG	AAG	AGC	ACC	1 7 5 2
Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr	
			5 3 0			5 3 5				5 4 0						
TAC	ATT	GAC	CCC	TTG	CCG	GAC	CTC	ATC	CAC	CCC	AGG	ACG	GGC	CGC	CTC	1 8 0 0
Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu	
			5 4 5			5 5 0				5 5 5				5 6 0		
CAC	ACC	CGC	TTC	AAC	CAG	ACG	GCC	ACG	GCC	ACG	GGC	AGG	CTA	AGT	AGC	1 8 4 8
His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Lcu	Ser	Ser	
			5 6 5				5 7 0						5 7 5			
TCC	GAT	CCC	AAC	CTC	CAG	AAC	ATC	CCC	GTC	CGC	ACC	CCG	CTT	GGG	CAG	1 8 9 6
Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln	
			5 8 0				5 8 5						5 9 0			
AGG	ATC	CGC	CGG	GCC	TTC	ATC	GCC	GAG	GAG	GGG	TGG	CTA	TTG	GTG	GCC	1 9 4 4
Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala	
			5 9 5				6 0 0				6 0 5					
CTG	GAC	TAT	AGC	CAG	ATA	GAG	CTC	AGG	GTC	CTG	GCC	CAC	CTC	TCC	GGC	1 9 9 2
Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly	
			6 1 0			6 1 5				6 2 0						
GAC	GAG	AAC	CTG	ATC	CGG	GTC	TTC	CAG	GAG	GGG	CGG	GAC	ATC	CAC	ACG	2 0 4 0
Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr	
			6 2 5			6 3 0				6 3 5				6 4 0		
GAG	ACC	GCC	AGC	TGG	ATG	TTC	GGC	GTC	CCC	CGG	GAG	GCC	GTG	GAC	CCC	2 0 8 8
Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Vai	Pro	Arg	Glu	Ala	Val	Asp	Pro	
			6 4 5				6 5 0						6 5 5			
CTG	ATG	CGC	CGG	GCG	GCC	AAG	ACC	ATC	AAC	TTC	GGG	GTC	CTC	TAC	GGC	2 1 3 6
Leu	Met	Arg	Arg	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly	
			6 6 0				6 6 5						6 7 0			
ATG	TCG	GCC	CAC	CGC	CTC	TCC	CAG	GAG	CTA	GCC	ATC	CCT	TAC	GAG	GAG	2 1 8 4
Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Lcu	Ala	Ile	Pro	Tyr	Glu	Glu	
			6 7 5				6 8 0						6 8 5			
GCC	CAG	GCC	TTC	ATT	GAG	CGC	TAC	TTT	CAG	AGC	TTC	CCC	AAG	GTG	CGG	2 2 3 2
Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val	Arg	
			6 9 0			6 9 5				7 0 0						
GCC	TGG	ATT	GAG	AAG	ACC	CTG	GAG	GAG	GGC	AGG	AGG	CGG	GGG	TAC	GTG	2 2 8 0
Ala	Trp	Ile	Glu	Lys	Thr	Lcu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr	Val	
			7 0 5			7 1 0				7 1 5				7 2 0		
GAG	ACC	CTC	TTC	GGC	CGC	CGC	CGC	TAC	GTG	CCA	GAC	CTA	GAG	GCC	CGG	2 3 2 8
Glu	Thr	Leu	Phe	Gly	Arg	Arg	Arg	Tyr	Val	Pro	Asp	Lcu	Glu	Ala	Arg	
			7 2 5				7 3 0						7 3 5			
GTG	AAG	AGC	GTG	CGG	GAG	GCG	GCC	GAG	CGC	ATG	GCC	TTC	AAC	ATG	CCC	2 3 7 6
Val	Lys	Ser	Val	Arg	Glu	Ala	Ala	Glu	Arg	Met	Ala	Phe	Asn	Met	Pro	
			7 4 0				7 4 5						7 5 0			
GTC	CAG	GGC	ACC	GCC	GCC	GAC	CTC	ATG	AAG	CTG	GCT	ATG	GTG	AAG	CTC	2 4 2 4
Val	Gln	Gly	Thr	Ala	Ala	Asp	Lcu	Met	Lys	Leu	Ala	Met	Val	Lys	Leu	
			7 5 5			7 6 0				7 6 5						
TTC	CCC	AGG	CTG	GAG	GAA	ATG	GGG	GCC	AGG	ATG	CTG	CTT	CAG	GTC	CAC	2 4 7 2
Phe	Pro	Arg	Leu	Glu	Glu	Met	Gly	Ala	Arg	Met	Lcu	Lcu	Gln	Val	His	
			7 7 0			7 7 5				7 8 0						
GAC	GAG	CTG	GTC	CTC	GAG	GCC	CCA	AAA	GAG	AGG	GCG	GAG	GCC	GTG	GCC	2 5 2 0
Asp	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val	Ala	
			7 8 5			7 9 0				7 9 5				8 0 0		

5,474,920

**55****56**

-continued

CGG	CTG	GCC	AAG	GAA	GTC	ATG	GAG	GGG	GTG	TAT	CCC	CTG	GCC	GTG	CCC	2568
Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val	Pro	
																805
																810
CTG	GAG	GTG	GAG	GTG	GGG	ATA	GGG	GAG	GAC	TGG	CTC	TCC	GCC	AAG	GAG	2616
Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Leu	Ser	Ala	Lys	Glu	
																820
																825
<b>TGATACCAACC</b>																2626

( 2 ) INFORMATION FOR SEQ ID NO:8:

## ( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 832 amino acids
- ( B ) TYPE: amino acid
- ( D ) TOPOLOGY: linear

## ( ii ) MOLECULE TYPE: protein

## ( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met	Arg	Gly	Met	Leu	Pro	Leu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Leu	Leu	
1				5					10					15		
Val	Asp	Gly	His	His	Leu	Ala	Tyr	Arg	Thr	Phe	His	Ala	Leu	Lys	Gly	
				20				25					30			
Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala	
				35				40				45				
Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val	
				50				55			60					
Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	His	His	Glu	Ala	Tyr	Gly	Gly	
	65			70					75				80			
Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Leu	
			85					90					95			
Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Leu	Leu	Gly	Leu	Ala	Arg	Leu	Glu	
			100					105					110			
Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Leu	Ala	Lys	Lys	
			115				120					125				
Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys	Asp	
	130				135						140					
Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu	Gly	
	145				150					155				160		
Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg	Pro	
	165							170					175			
Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Ser	Asp	Asn	
	180						185					190				
Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu	Leu	
	195						200					205				
Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Lys	Asn	Leu	Asp	Arg	Leu		
	210					215				220						
Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Leu	Ala	His	Met	Asp	Asp	Leu	Lys	
	225				230					235				240		
Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Glu	Val	
			245					250					255			
Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala	Ile	
	260					265							270			
Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Pro	Leu	His	Glu	Phe	Gly	Leu	Leu	
	275					280						285				
Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu	Gly	
	290					295					300					

-continued

Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	Asp
305					310					315					320
Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro
			325						330						335
Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu
			340					345							350
Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro
						360									365
Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn
						375									380
Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu
					390					395					400
Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu
				405					410						415
Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu
			420					425							430
Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly
							440								445
Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala
						455									460
Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His
					470					475					480
Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp
						485				490					495
Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys	Arg
				500					505						510
Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile
						520									525
Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr
						535					540				
Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu
					550					555					560
His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser
					565				570						575
Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln
					580				585						590
Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala
						600									605
Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly
					615										620
Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr
					630					635					640
Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro
					645				650						655
Leu	Met	Arg	Arg	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly
					660				665						670
Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu	Glu
						680									685
Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val	Arg
					695						700				
Ala	Trp	Ile	Glu	Lys	Thr	Leu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr	Val
					710					715					720
Glu	Thr	Leu	Phe	Gly	Arg	Arg	Arg	Tyr	Val	Pro	Asp	Leu	Glu	Ala	Arg

5,474,920

59

60

-continued

7 2 5	7 3 0	7 3 5
Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro 7 4 0 7 4 5 7 5 0		
Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu 7 5 5 7 6 0 7 6 5		
Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His 7 7 0 7 7 5 7 8 0		
Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala 7 8 5 7 9 0 7 9 5 8 0 0		
Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro 8 0 5 8 1 0 8 1 5		
Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu 8 2 0 8 2 5 8 3 0		

( 2 ) INFORMATION FOR SEQ ID NO:9:

( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 2626 base pairs
- ( B ) TYPE: nucleic acid
- ( C ) STRANDEDNESS: single
- ( D ) TOPOLOGY: linear

( i i ) MOLECULE TYPE: DNA (genomic)

( i i i ) HYPOTHETICAL: NO

( i x ) FEATURE:

- ( A ) NAME/KEY: mutation
- ( B ) LOCATION: replace(89, "g")
- ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 89 of the native Taq DNA polymerase nucleotide sequence of C to G."

( i x ) FEATURE:

- ( A ) NAME/KEY: mutation
- ( B ) LOCATION: replace(934, "a")
- ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 934 of the native Taq DNA polymerase nucleotide sequence of T to A. This results in an amino acid change of Phe to Ile."

( i x ) FEATURE:

- ( A ) NAME/KEY: mutation
- ( B ) LOCATION: replace(962, "c")
- ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 962 of the native Taq DNA polymerase nucleotide sequence of T to C. This results in an amino acid change of Leu to Pro."

( i x ) FEATURE:

- ( A ) NAME/KEY: mutation
- ( B ) LOCATION: replace(2535, "a")
- ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 2535 of the native Taq DNA polymerase nucleotide sequence of G to A. This mutation is conservative."

( i x ) FEATURE:

- ( A ) NAME/KEY: mutation
- ( B ) LOCATION: replace(337, "a")
- ( D ) OTHER INFORMATION: /note="This mutation results in a nucleotide alteration at position 337 of the native Taq DNA polymerase nucleotide sequence of T to C. This change results in an amino acid change of Phe to Leu."

( i x ) FEATURE:

- ( A ) NAME/KEY: CDS
- ( B ) LOCATION: 121..2619

( i x ) FEATURE:

- ( A ) NAME/KEY: mat\_peptide
- ( B ) LOCATION: 121..2616

-continued

## ( i x ) FEATURE:

( A ) NAME/KEY: -

( B ) LOCATION: 1..2619

( D ) OTHER INFORMATION: /note="pTarf2"

## ( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AAGCTCAGAT	CTACCTGCCT	GAGGGCGTCC	GGTTCCAGCT	GGCCCTTCCC	GAGGGGGAGA	6 0
GGGAGGGCGTT	TCTAAAAGCC	CTTCAGGAGG	CTACCCGGGG	GCGGGTGGTG	GAAGGGTAAC	120
ATG AGG GGG ATG CTG CCC CTC TTT GAG CCC AAG GGC CGG GTC CTC CTG						168
Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu						
1 5 10 15						
GTG GAC GGC CAC CAC CTG GCC TAC CGC ACC TTC CAC GCC CTG AAG GGC						216
Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly						
20 25 30						
CTC ACC ACC AGC CGG GGG GAG CCG GTG CAG GCG GTC TAC GGC TTC GCC						264
Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala						
35 40 45						
AAG AGC CTC CTC AAG GCC CTC AAG GAG GAC GGG GAC GCG GTG ATC GTG						312
Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val						
50 55 60						
GTC TTT GAC GCC AAG GCC CCC TCC CTC CGC CAC GAG GCC TAC GGG GGG						360
Val Phe Asp Ala Lys Ala Pro Ser Leu Arg His Glu Ala Tyr Gly Gly						
65 70 75 80						
TAC AAG GCG GGC CGG GCC CCC ACG CCG GAG GAC TTT CCC CGG CAA CTC						408
Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu						
85 90 95						
GCC CTC ATC AAG GAG CTG GTG GAC CTC CTG GGG CTG GCG CGC CTC GAG						456
Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Lec Ala Arg Lec Glu						
100 105 110						
GTC CCG GGC TAC GAG GCG GAC GAC GTC CTG GCC AGC CTG GCC AAG AAG						504
Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys						
115 120 125						
GCG GAA AAG GAG GGC TAC GAG GTC CGC ATC CTC ACC GCC GAC AAA GAC						552
Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp						
130 135 140						
CTT TAC CAG CTC CTT TCC GAC CGC ATC CAC GTC CTC CAC CCC GAG GGG						600
Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly						
145 150 155 160						
TAC CTC ATC ACC CCG GCC TGG CTT TGG GAA AAG TAC GGC CTG AGG CCC						648
Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro						
165 170 175						
GAC CAG TGG GCC GAC TAC CGG GCC CTG ACC GGG GAC GAG TCC GAC AAC						696
Asp Gln Trp Ala Asp Tyr Arg Ala Lec Thr Gly Asp Glu Ser Asp Asn						
180 185 190						
CTT CCC GGG GTC AAG GGC ATC GGG GAG AAG ACG GCG AGG AAG CTT CTG						744
Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Lec Leu						
195 200 205						
GAG GAG TGG GGG AGC CTG GAA GCC CTC CTC AAG AAC CTG GAC CGG CTG						792
Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Lec Asp Arg Leu						
210 215 220						
AAG CCC GCC ATC CGG GAG AAG ATC CTG GCC CAC ATG GAC GAT CTG AAG						840
Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys						
225 230 235 240						
CTC TCC TGG GAC CTG GCC AAG GTG CGC ACC GAC CTG CCC CTG GAG GTG						888
Leu Ser Trp Asp Lec Ala Lys Val Arg Thr Asp Lec Pro Lec Glu Val						
245 250 255						
GAC TTC GCC AAA AGG CGG GAG CCC GAC CGG GAG AGG CTT AGG GCC ATT						936
Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Lec Arg Ala Ile						
260 265 270						

-continued

CTG	GAG	AGG	CTT	GAG	TTT	GGC	AGC	CCC	CTC	CAC	GAG	TTC	GGC	CTT	CTG		9 8 4
Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Pro	Leu	His	Glu	Phe	Gly	Leu	Leu		
275							280					285					
GAA	AGC	CCC	AAG	GCC	CTG	GAG	GAG	GCC	CCC	TGG	CCC	CCG	CCG	GAA	GGG		1 0 3 2
Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu	Gly		
290						295					300						
GCC	TTC	GTG	GGC	TTT	GTG	CTT	TCC	CGC	AAG	GAG	CCC	ATG	TGG	GCC	GAT		1 0 8 0
Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	Asp		
305						310					315					320	
CTT	CTG	GCC	CTG	GCC	GCC	AGG	GGG	GGC	CGG	GTC	CAC	CGG	GCC	CCC			1 1 2 8
Leu	Leu	Ala	Leu	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro			
						325					330					335	
GAG	CCT	TAT	AAA	GCC	CTC	AGG	GAC	CTG	AAG	GAG	GCG	CGG	GGG	CTT	CTC		1 1 7 6
Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu		
						340					345					350	
GCC	AAA	GAC	CTG	AGC	GTT	CTG	GCC	CTG	AGG	GAA	GGC	CTT	GGC	CTC	CCG		1 2 2 4
Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro		
						355					360					365	
CCC	GGC	GAC	GAC	CCC	ATG	CTC	CTC	GCC	TAC	CTC	CTG	GAC	CCT	TCC	AAC		1 2 7 2
Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn		
						370					375					380	
ACC	ACC	CCC	GAG	GGG	GTG	GCC	CGG	CGC	TAC	GGC	GGG	GAG	TGG	ACG	GAG		1 3 2 0
Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu		
						385					390					400	
GAG	GCG	GGG	GAG	CGG	GCC	GCC	CTT	TCC	GAG	AGG	CTC	TTC	GCC	AAC	CTG		1 3 6 8
Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu		
						405					410					415	
TGG	GGG	AGG	CTT	GAG	GGG	GAG	GAG	AGG	CTC	CTT	TGG	CTT	TAC	CGG	GAG		1 4 1 6
Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu		
						420					425					430	
GTG	GAG	AGG	CCC	CTT	TCC	GCT	GTC	CTG	GCC	CAC	ATG	GAG	GCC	ACG	GGG		1 4 6 4
Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly		
						435					440					445	
GTG	CGC	CTG	GAC	GTG	GCC	TAT	CTC	AGG	GCC	TTG	TCC	CTG	GAG	GTG	GCC		1 5 1 2
Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala		
						450					455					460	
GAG	GAG	ATC	GCC	CGC	CTC	GAG	GCC	GAG	GTC	TTC	CGC	CTG	GCC	GGC	CAC		1 5 6 0
Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His		
						465					470					480	
CCC	TTC	AAC	CTC	AAC	TCC	CGG	GAC	CAG	CTG	GAA	AGG	GTC	CTC	TTT	GAC		1 6 0 8
Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp		
						485					490					495	
GAG	CTA	GGG	CTT	CCC	GCC	ATC	GGC	AAG	ACG	GAG	AAG	ACC	GGC	AAG	CGC		1 6 5 6
Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys	Arg		
						500					505					510	
TCC	ACC	AGC	GCC	GCC	GTC	CTG	GAG	GCC	CTC	CGC	GAG	GCC	CAC	CCC	ATC		1 7 0 4
Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile		
						515					520					525	
GTG	GAG	AAG	ATC	CTG	CAG	TAC	CGG	GAG	CTC	ACC	AAG	CTG	AAG	AGC	ACC		1 7 5 2
Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr		
						530					535					540	
TAC	ATT	GAC	CCC	TTG	CCG	GAC	CTC	ATC	CAC	CCC	AGG	ACG	GGC	CGC	CTC		1 8 0 0
Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu		
						545					550					560	
CAC	ACC	CGC	TTC	AAC	CAG	ACG	GCC	ACG	GCC	ACG	GGC	AGG	CTA	AGT	AGC		1 8 4 8
His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser		
						565					570					575	
TCC	GAT	CCC	AAC	CTC	CAG	AAC	ATC	CCC	GTC	CGC	ACC	CCG	CTT	GGG	CAG		1 8 9 6
Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln		

5,474,920

65

66

-continued

	5 8 0	5 8 5	5 9 0	
AGG ATC CGC CGG GCC TTC ATC GCC GAG GAG GGG TGG CTA TTG GTG GCC				1 9 4 4
Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala				
5 9 5	6 0 0		6 0 5	
CTG GAC TAT AGC CAG ATA GAG CTC AGG GTG CTG GCC CAC CTC TCC GGC				1 9 9 2
Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly				
6 1 0	6 1 5		6 2 0	
GAC GAG AAC CTG ATC CGG GTC TTC CAG GAG GGG CGG GAC ATC CAC ACG				2 0 4 0
Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His Thr				
6 2 5	6 3 0		6 3 5	6 4 0
GAG ACC GCC AGC TGG ATG TTC GGC GTC CCC CGG GAG GCC GTG GAC CCC				2 0 8 8
Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro				
6 4 5		6 5 0		6 5 5
CTG ATG CGC CGG GCG GCC AAG ACC ATC AAC TTC GGG GTC CTC TAC GGC				2 1 3 6
Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly				
6 6 0	6 6 5		6 7 0	
ATG TCG GCC CAC CGC CTC TCC CAG GAG CTA GCC ATC CCT TAC GAG GAG				2 1 8 4
Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu				
6 7 5	6 8 0		6 8 5	
GCC CAG GCC TTC ATT GAG CGC TAC TTT CAG AGC TTC CCC AAG GTG CGG				2 2 3 2
Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg				
6 9 0	6 9 5		7 0 0	
GCC TGG ATT GAG AAG ACC CTG GAG GAG GGC AGG AGG CGG GGG TAC GTG				2 2 8 0
Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val				
7 0 5	7 1 0		7 1 5	7 2 0
GAG ACC CTC TTC GGC CGC CGC CGC TAC GTG CCA GAC CTA GAG GCC CGG				2 3 2 8
Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg				
7 2 5		7 3 0		7 3 5
GTG AAG AGC GTG CGG GAG GCG GCC GAG CGC ATG GCC TTC AAC ATG CCC				2 3 7 6
Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro				
7 4 0		7 4 5		7 5 0
GTC CAG GGC ACC GCC GAC CTC ATG AAG CTG GCT ATG GTG AAG CTC				2 4 2 4
Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu				
7 5 5	7 6 0		7 6 5	
TTC CCC AGG CTG GAG GAA ATG GGG GCC AGG ATG CTC CTT CAG GTC CAC				2 4 7 2
Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His				
7 7 0	7 7 5		7 8 0	
GAC GAG CTG GTC CTC GAG GCC CCA AAA GAG AGG GCG GAG GCC GTG GCC				2 5 2 0
Asp Glu Leu Val Lcu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala				
7 8 5	7 9 0		7 9 5	8 0 0
CGG CTG GCC AAG GAA GTC ATG GAG GGG GTG TAT CCC CTG GCC GTG CCC				2 5 6 8
Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro				
8 0 5		8 1 0		8 1 5
CTG GAG GTG GAG GTG GGG ATA GGG GAG GAC TGG CTC TCC GCC AAG GAG				2 6 1 6
Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu				
8 2 0		8 2 5		8 3 0
TGATACCAACC				2 6 2 6

( 2 ) INFORMATION FOR SEQ ID NO:10:

#### ( i ) SEQUENCE CHARACTERISTICS:

( A ) LENGTH: 832 amino acids

( B ) TYPE: amino acid

M e t   A r g   G l y   M e t   L e u   P r o   L e u   P h e   G l u   P r o   L y s   G l y   A r g   V a l   L e u   L e u

-continued

Val	Asp	Gly	His	His	Leu	Ala	Tyr	Arg	Thr	Phe	His	Ala	Leu	Lys	Gly
20								25					30		
Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala
35						40						45			
Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val
50						55					60				
Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Leu	Arg	His	Glu	Ala	Tyr	Gly	Gly
65						70				75					80
Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Leu
85									90					95	
Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Leu	Leu	Gly	Leu	Ala	Arg	Leu	Glu
100								105					110		
Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Leu	Ala	Lys	Lys
115						120						125			
Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys	Asp
130						135					140				
Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu	Gly
145						150				155					160
Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg	Pro
165									170					175	
Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Ser	Asp	Asn
180								185					190		
Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu	Leu
195								200					205		
Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Leu	Lys	Asn	Leu	Asp	Arg	Leu
210						215					220				
Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Leu	Ala	His	Met	Asp	Asp	Leu	Lys
225						230				235					240
Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Glu	Val
245								250					255		
Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala	Ile
260								265					270		
Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Pro	Leu	His	Glu	Phe	Gly	Leu	Leu
275								280					285		
Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu	Gly
290						295					300				
Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	Asp
305						310				315					320
Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro
325								330					335		
Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu
340								345					350		
Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro
355								360					365		
Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn
370						375					380				
Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu
385						390				395					400
Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu
405								410					415		
Trp	Gly	Arg	Leu	Glu	Gly	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu	
420								425					430		
Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly

5,474,920

69

70

-continued

	4 3 5	4 4 0	4 4 5												
Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala
4 5 0						4 5 5					4 6 0				
Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His
4 6 5					4 7 0					4 7 5					4 8 0
Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp
					4 8 5				4 9 0						4 9 5
Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys	Arg
			5 0 0					5 0 5					5 1 0		
Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile
						5 2 0						5 2 5			
Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr
						5 3 5					5 4 0				
Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu
					5 5 0					5 5 5					5 6 0
His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser
					5 6 5				5 7 0					5 7 5	
Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln
								5 8 5					5 9 0		
Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala
						6 0 0						6 0 5			
Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly
						6 1 5						6 2 0			
Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr
					6 3 0					6 3 5					6 4 0
Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro
					6 4 5				6 5 0					6 5 5	
Leu	Met	Arg	Arg	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly
						6 6 0		6 6 5					6 7 0		
Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu	Glu
						6 7 5		6 8 0				6 8 5			
Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val	Arg
						6 9 0		6 9 5			7 0 0				
Ala	Trp	Ile	Glu	Lys	Thr	Leu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr	Val
					7 0 5		7 1 0			7 1 5					7 2 0
Glu	Thr	Leu	Phe	Gly	Arg	Arg	Arg	Tyr	Val	Pro	Asp	Leu	Glu	Ala	Arg
				7 2 5					7 3 0					7 3 5	
Val	Lys	Ser	Val	Arg	Glu	Ala	Ala	Glu	Arg	Met	Ala	Phe	Asn	Met	Pro
				7 4 0				7 4 5					7 5 0		
Val	Gln	Gly	Thr	Ala	Ala	Asp	Leu	Met	Lys	Leu	Ala	Met	Val	Lys	Leu
						7 5 5		7 6 0				7 6 5			
Phe	Pro	Arg	Leu	Glu	Glu	Met	Gly	Ala	Arg	Met	Leu	Leu	Gln	Val	His
						7 7 0		7 7 5			7 8 0				
Asp	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val	Ala
					7 8 5			7 9 0			7 9 5				8 0 0
Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val	Pro
					8 0 5				8 1 0					8 1 5	
Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Leu	Ser	Ala	Lys	Glu
					8 2 0				8 2 5					8 3 0	

( 2 ) INFORMATION FOR SEO ID NO:11:

( i ) SEQUENCE CHARACTERISTICS:  
      ( A ) LENGTH: 18 base pairs

5,474,920

71

72

-continued

- 
- ( B ) TYPE: nucleic acid
  - ( C ) STRANDEDNESS: single
  - ( D ) TOPOLOGY: linear

( i i ) MOLECULE TYPE: cDNA

( i i i ) HYPOTHETICAL: NO

( i x ) FEATURE:

- ( A ) NAME/KEY: -
- ( B ) LOCATION: 1..18
- ( D ) OTHER INFORMATION: /note="PCR reverse primer used for pUC18"

( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CAGGAAACAG CTATGACC

1 8

( 2 ) INFORMATION FOR SEQ ID NO:12:

( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 15 base pairs
- ( B ) TYPE: nucleic acid
- ( C ) STRANDEDNESS: single
- ( D ) TOPOLOGY: linear

( i i ) MOLECULE TYPE: cDNA

( i i i ) HYPOTHETICAL: NO

( i x ) FEATURE:

- ( A ) NAME/KEY: -
- ( B ) LOCATION: 11..15
- ( D ) OTHER INFORMATION: /note="PCR sequencing primer 628A used for pUC18"

( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CCCAAAGCCA GGCG

1 5

( 2 ) INFORMATION FOR SEQ ID NO:13:

( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 15 base pairs
- ( B ) TYPE: nucleic acid
- ( C ) STRANDEDNESS: double
- ( D ) TOPOLOGY: linear

( i i ) MOLECULE TYPE: cDNA

( i i i ) HYPOTHETICAL: NO

( i x ) FEATURE:

- ( A ) NAME/KEY: -
- ( B ) LOCATION: 1..15
- ( D ) OTHER INFORMATION: /note="Sequencing primer 1155A"

( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CAGGTCCCTG AGGGC

1 5

( 2 ) INFORMATION FOR SEQ ID NO:14:

( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 46 base pairs
- ( B ) TYPE: nucleic acid
- ( C ) STRANDEDNESS: single
- ( D ) TOPOLOGY: linear

( i i ) MOLECULE TYPE: cDNA

( i i i ) HYPOTHETICAL: NO

( i x ) FEATURE:

- ( A ) NAME/KEY: -
- ( B ) LOCATION: 1..46

-continued

( D ) OTHER INFORMATION: /note="pUC18 - pLSM5 5'junction"

( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:14:

A A T T C A C A C    A G G A A A C A G C    T A T G A C C A T G    A T T A C G A A T T    C T A A A A

4 6

( 2 ) INFORMATION FOR SEQ ID NO:15:

( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 63 base pairs
- ( B ) TYPE: nucleic acid
- ( C ) STRANDEDNESS: single
- ( D ) TOPOLOGY: linear

( i i ) MOLECULE TYPE: cDNA

( i i i ) HYPOTHETICAL: NO

( i x ) FEATURE:

- ( A ) NAME/KEY: -
- ( B ) LOCATION: 1..63
- ( D ) OTHER INFORMATION: /note="pUC18 - pLSM5 3'sequenc junction"

( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:15:

C A A G G A G T G A    G A T T C T C T A G    A G T C G A C C T G    C A G G C A T G C A    A G C T T G G C A C    T G G C C G T C G T

6 0

T T T

6 3

**1.** A modified Taq polymerase gene comprising the native Taq DNA polymerase gene wherein the nucleotide at position 193 is T and the nucleotide at position 504 is A.

**2.** A modified Taq DNA polymerase gene comprising the native Taq DNA polymerase gene wherein the nucleotide at position 89 is G, the nucleotide at position 193 is T, the nucleotide at position 504 is A, the nucleotide at position 934 is A, the nucleotide at position 962 is C, and the nucleotide at position 2535 is A.

**3.** A modified Taq polymerase comprising the native Taq DNA polymerase wherein the amino acid at position 25 is Cys.

**4.** A modified Taq polymerase comprising the native Taq DNA polymerase wherein the amino acid at position 25 is Cys, the amino acid at position 272 is Ile, and the amino acid at position 281 is Pro.

**5.** A modified Taq DNA polymerase gene comprising the native Taq DNA polymerase gene wherein the nucleotide at position 341 is A.

**6.** A modified Taq DNA polymerase gene comprising the native Taq DNA polymerase gene wherein the nucleotide at

30 position 89 is G, the nucleotide at position 341 is A, the nucleotide at position 934 is A, the nucleotide at position 962 is C, and the nucleotide at position 2535 is A.

**7.** A modified Taq DNA polymerase comprising the native Taq DNA polymerase wherein the amino acid at position 74 is His.

**8.** A modified Taq DNA polymerase comprising the native Taq DNA polymerase wherein the amino acid at position 74 is His, the amino acid at position 272 is Ile, and the amino acid at position 281 is Pro.

**9.** Host cells that are transfected with the modified Taq DNA polymerase gene of claim **1** and that express the gene.

**10.** Host cells that are transfected with the modified Taq DNA polymerase gene of claim **2** and that express the gene.

**11.** Host cells that are transfected with the modified Taq DNA polymerase gene of claim **5** and that express the gene.

**12.** Host cells that are transfected with the modified Taq DNA polymerase gene of claim **6** and that express the gene.

\* \* \* \* \*